On this page
Quick Reference
Overview and Recommendations
Background
- •Understand the Fourth Universal Definition of Myocardial Infarction, which classifies AMI into five types based on pathophysiology. Type 1 is spontaneous MI due to plaque rupture or erosion; Type 2 results from supply-demand imbalance (e.g., anemia, tachycardia); Type 3 is sudden cardiac death; Type 4 is related to (PCI); and Type 5 is related to coronary artery bypass grafting (CABG).
- •Distinguish between and based on the initial electrocardiogram (ECG). STEMI requires immediate reperfusion due to transmural ischemia, while NSTEMI involves subendocardial ischemia and is managed with urgent or early invasive strategies depending on risk stratification.
- •Recognize the significance of (CS), the most lethal complication of AMI. It is characterized by systemic hypoperfusion due to cardiac pump failure and is staged from A (at risk) to E (extremis) using the SCAI classification system.
- •Identify non-atherosclerotic causes of MI, particularly in younger patients and women. (SCAD) is the leading cause of pregnancy-associated MI, while (Myocardial Infarction with Non-Obstructed Coronary Arteries) occurs in 5-10% of cases and requires specialized imaging like Cardiac MRI for diagnosis.
- •Appreciate the time-dependent nature of myocardial necrosis. The "progressive phase" of active necrosis begins at symptom onset, making the "door-to-balloon" time (target < 90 minutes) the most critical metric for improving survival in obstructive cases.
Evaluation
- •Suspect AMI in any patient presenting with acute chest pain, pressure, or discomfort, particularly if it radiates to the left arm, neck, or jaw. Be vigilant for atypical presentations in women, the elderly, and patients with diabetes, who may present with isolated dyspnea, nausea, or epigastric pain.
- •Obtain a 12-lead ECG within 10 minutes of first medical contact. Look for persistent ST-segment elevation in two contiguous leads (≥1 mm in most leads, or age/sex-specific thresholds in V2-V3) to diagnose STEMI.
- •Identify "Occlusion Myocardial Infarction" (OMI) patterns that may not meet formal STEMI criteria but indicate acute occlusion. These include de Winter T-waves (upsloping ST-depression with tall, symmetric T-waves), hyperacute T-waves, and Wellens' syndrome (biphasic or deeply inverted T-waves in V2-V3).
- •Order high-sensitivity cardiac troponin (hs-cTn) immediately at presentation (H0). Utilize the H0/H1 or H0/H2 rapid rule-out/rule-in algorithms; a very low H0 value in a patient symptomatic for >3 hours can often rule out AMI, while a significant absolute delta (change) at 1 or 2 hours suggests acute injury.
- •Perform a targeted physical examination to assess for hemodynamic stability and complications. Use the Killip classification: Class I (no heart failure), Class II (rales, S3 gallop), Class III (pulmonary edema), and Class IV ( with hypotension and hypoperfusion).
- •Rule out life-threatening mimics using the "Triple Rule Out" approach if the diagnosis is ambiguous. Consider (tearing pain, BP discrepancy), (pleuritic pain, tachycardia), and tension pneumothorax.
- •Calculate the GRACE or TIMI risk score to guide the urgency of intervention in NSTEMI. High-risk features (GRACE >140, dynamic ST changes) warrant an early invasive strategy within 24 hours.
- •Utilize point-of-care to identify regional wall motion abnormalities, which support the diagnosis of AMI and help exclude mechanical complications like papillary muscle rupture or ventricular septal defects.
- •Screen for metabolic mimics such as severe , which can produce "pseudo-infarction" ST-elevation patterns on ECG, especially in patients with known renal failure.
- •Consider Cardiac Magnetic Resonance (CMR) imaging within 7-14 days for patients with suspected . CMR is the gold standard for differentiating MI from or by identifying specific patterns of late gadolinium enhancement (LGE).
Management
- •Administer Aspirin 324 mg (chewed) immediately to all patients with suspected ACS unless a true allergy exists. This provides rapid platelet inhibition and is a cornerstone of early therapy.
- •Initiate a second antiplatelet agent (P2Y12 inhibitor) as soon as possible. For STEMI or high-risk NSTEMI, preferred agents include Ticagrelor 180 mg loading dose followed by 90 mg BID, or Prasugrel 60 mg loading dose (only if coronary anatomy is known and no history of stroke/TIA).
- •Provide anticoagulation with Unfractionated Heparin (UFH) 60 U/kg bolus (max 4000 U) followed by 12 U/kg/hr infusion, or Enoxaparin 1 mg/kg SC BID. UFH is preferred if the patient is proceeding immediately to the cath lab.
- •Activate the cardiac catheterization laboratory immediately for any patient with STEMI. The goal is primary PCI with a door-to-balloon time of < 90 minutes at PCI-capable centers or < 120 minutes if transfer is required.
- •Administer Fibrinolytic therapy (e.g., Tenecteplase weight-based bolus) only if primary PCI cannot be performed within 120 minutes of diagnosis and there are no contraindications (e.g., recent intracranial hemorrhage, active bleeding).
- •Restrict supplemental oxygen to patients with SaO2 < 90% or PaO2 < 60 mmHg. Routine oxygen in normoxic patients may cause coronary vasoconstriction and increase infarct size.
- •Manage ischemic pain with Sublingual Nitroglycerin 0.4 mg every 5 minutes (up to 3 doses). Avoid nitrates in patients with right ventricular infarction (leads V3R/V4R elevation) or recent phosphodiesterase inhibitor use (e.g., sildenafil).
- •Stabilize by maintaining a Mean Arterial Pressure (MAP) ≥ 65 mmHg. Use Norepinephrine 0.05–1.0 µg/kg/min as the first-line vasopressor; add Dobutamine 2.5–20 µg/kg/min if hypoperfusion persists despite adequate MAP.
- •Consider early mechanical circulatory support (MCS) with a microaxial flow pump (e.g., Impella) in patients with refractory cardiogenic shock (SCAI Stage D/E) to provide left ventricular unloading.
- •Initiate high-intensity (e.g., Atorvastatin 80 mg daily) as soon as possible, regardless of baseline LDL levels, for their pleiotropic plaque-stabilizing effects.
- •Start an ACE inhibitor (e.g., Lisinopril 5 mg daily) within 24 hours in patients with LVEF < 40%, hypertension, or diabetes, provided they are hemodynamically stable without hypotension.
- •Administer oral Beta-blockers (e.g., Metoprolol succinate 25-50 mg daily) within the first 24 hours only in stable patients. Avoid in those with signs of heart failure, low output states, or risk of cardiogenic shock.
- •Prescribe Mineralocorticoid Receptor Antagonists (MRA) like Eplerenone 25 mg daily for patients already on ACEi and Beta-blockers who have an LVEF ≤ 40% and either symptomatic heart failure or diabetes.
- •Refer all AMI survivors to a formal cardiac rehabilitation program. Participation significantly reduces all-cause mortality and improves functional capacity post-discharge.
- •Discharge criteria include hemodynamic stability for 24-48 hours, successful revascularization, absence of high-grade arrhythmias, and a clear plan for dual antiplatelet therapy (DAPT) adherence, typically for 12 months.
Board Review — High Yield
- •Type 2 MI — Myocardial injury due to supply-demand mismatch (e.g., sepsis, anemia) rather than primary plaque rupture.
- •Killip Class IV — Represents cardiogenic shock; the highest mortality risk category in AMI.
- •de Winter T-waves — Upsloping ST-depression with tall, peaked T-waves in precordial leads; signifies acute LAD occlusion.
- •SCAD — Spontaneous Coronary Artery Dissection; the most common cause of MI in pregnant and postpartum women.
- •S1Q3T3 — Classic but non-specific ECG finding for pulmonary embolism, a major differential for AMI.
- •H0/H1 Protocol — Use of high-sensitivity troponin at 0 and 1 hour to rapidly rule out (low delta) or rule in (high delta) AMI.
- •Right Ventricular Infarct — Suspect with inferior MI + ST-elevation in V4R; treat with fluids, avoid nitrates/diuretics.
- •Dressler Syndrome — Post-MI pericarditis occurring weeks later; autoimmune-mediated, treated with NSAIDs/Colchicine.
Deep Dive — Evidence Details
Definition, Synonyms, and Classification
- ▸AMI is defined as myocardial necrosis due to ischemia, often driven by IL-6 mediated inflammation [174].
- ▸STAMI is a newly identified overlap phenotype where Takotsubo syndrome and AMI occur simultaneously [175].
- ▸STEMI and NSTEMI remain the primary classifications, but atypical 'Non-Chest Pain' presentations carry a worse prognosis [184].
- ▸High-sensitivity troponin (hs-cTnI) 0/2-hour algorithms are validated for rapid triage in the emergency department [172].
- ▸The NT-proBNP/albumin ratio is a novel marker for predicting pericardial effusion in young AMI patients (<45 years) [180].
- ▸Severe obesity combined with high CRP (>2 mg/L) significantly increases long-term mortality in NSTEMI [179].
Definition and Core Pathophysiology
Acute myocardial infarction (AMI) is defined as myocardial necrosis resulting from acute ischemia [174]. The clinical diagnosis is established by evidence of myocardial injury—typically detected via elevated cardiac biomarkers—in the setting of clinical evidence of acute myocardial ischemia [172]. Recent evidence emphasizes that AMI is not merely a vascular event but a complex inflammatory process; interleukin-6 (IL-6) pathways significantly contribute to ischemia-reperfusion injury and subsequent myocardial damage [174].
Synonyms and Emerging Phenotypes
While commonly referred to as a "heart attack," AMI encompasses several distinct clinical and electrocardiographic phenotypes. A newly recognized overlap phenotype is STAMI (Superimposed Takotsubo and Acute Myocardial Infarction), where AMI and Takotsubo syndrome (TTS) coexist [175]. Historically, TTS was a diagnosis of exclusion requiring the absence of obstructive coronary disease, but pooled analyses now confirm that 57% of STAMI cases present as STEMI and 41% as NSTEMI, often in older women (mean age 67 years) [175].
Classification by Electrocardiographic Presentation
AMI is primarily classified based on the presence or absence of ST-segment elevation on the electrocardiogram (ECG):
- ST-Elevation Myocardial Infarction (STEMI): Characterized by transmural ischemia and persistent ST-segment elevation. It is often associated with higher peak levels of biomarkers such as creatine kinase (CK) and cardiac troponin T (cTnT) [182].
- Non-ST-Elevation Myocardial Infarction (NSTEMI): Characterized by subendocardial ischemia without persistent ST-elevation. Critically ill NSTEMI patients with severe obesity and systemic inflammation (CRP >2 mg/L) face significantly higher 10-year all-cause mortality [179]C.
Clinical Subtypes and Atypical Presentations
Classification also accounts for the clinical context of the presentation:
- Type 1 MI: Spontaneous myocardial infarction related to ischemia due to a primary coronary event (e.g., plaque erosion or rupture) [188].
- Non-Chest Pain (NCP) STEMI: A significant proportion of patients present without classic cardiac chest pain. These patients often experience delays in care and have worse short- and long-term outcomes compared to those with typical symptoms [184].
- Young AMI: Defined as AMI occurring in patients <45 years. This group is increasingly recognized, with specific risks such as pericardial effusion (PE) which can be predicted by the NT-proBNP/albumin ratio [180].
Risk Stratification and Diagnostic Classification Tools
Modern classification integrates various scoring systems and biomarkers to predict complexity and outcomes:
- SCARE Score: A tool used by emergency medical communication centers to discriminate AMI in patients calling for non-traumatic chest pain [173].
- SYNTAX Score: Quantifies the complexity of coronary anatomy to inform revascularization strategies, though it traditionally requires invasive angiography [183].
- ASCVD Models: Traditional models like the Framingham Risk Score (FRS) and ACC/AHA ASCVD 2013 are used to classify 10-year pre-event risk, though their performance varies in specific populations like South Asians [176].
- Inflammatory Indices: The neutrophil-to-lymphocyte ratio (NLR) and neutrophil-to-lymphocyte × platelet ratio (NLPR) are used to classify the severity of myocardial injury at presentation [185].
| Biomarker | Clinical Utility | Key Threshold/Finding |
|---|---|---|
| hs-cTnI | Rapid 0/2-hour triage | Validated for POC i-STAT assays [172] |
| IL-6 | Inflammatory mediator | Target for tocilizumab to reduce damage [174] |
| NT-proBNP/ALB | Risk stratification in young patients | Predicts in-hospital pericardial effusion [180] |
| LRG1 | Non-invasive anatomy assessment | Correlates with complex SYNTAX scores [183] |
| HGI | Glycemic control marker | Higher HGI associated with better survival in NSTEMI [186] |
| XBP1 & PLA2 | Myocardial injury prediction | Prognostic for injury severity in STEMI [191] |
Etiology and Triggering Factors
- ▸Atherosclerotic plaque disruption with thrombosis is the principal AMI mechanism, but plaque erosion, SCAD, vasospasm, inflammatory injury, infection, and PCI-related injury are also recognized pathways. [198][31][199][231][196]
- ▸OCT-defined high-risk plaque features include thin-cap fibroatheroma, lipid arc >180°, macrophages, and minimum luminal area <3.5 mm². [58]
- ▸Diabetes is associated with differences in coronary calcium, stenosis, and calcified, noncalcified, low-attenuation, and total plaque burden. [33]
- ▸CHIP and JAK2 V617F are linked to culprit-lesion biology, plaque erosion or rupture, and adverse outcomes in AMI cohorts. [54][198]
- ▸Obstructive sleep apnea and nocturnal hypoxemia were investigated as potential modifiers of the circadian timing of MI onset. [195]
Overview
Acute myocardial infarction (AMI) results from an abrupt imbalance between myocardial oxygen supply and demand, most often because a coronary atherosclerotic lesion becomes thrombogenic and obstructs flow. Contemporary imaging and clinical studies support several interacting etiologic pathways: plaque rupture, plaque erosion, calcified or lipid-rich plaque complications, spontaneous coronary artery dissection (SCAD), coronary vasospasm, and less common inflammatory or infectious coronary injury. [230][198][31][199][231]C
Atherosclerotic plaque disruption and thrombosis
Atherosclerotic plaque disruption remains a major substrate for AMI. Coronary CT angiography and intracoronary optical coherence tomography (OCT) characterize plaques as predominantly lipidic, calcific, or fibrotic; in the ILUMIEN IV OCT substudy, a lipidic lesion was defined by a maximum lipid arc of ≥180° or the presence of a thin-cap fibroatheroma, whereas a calcific lesion had a maximum calcium arc of ≥180°. [230] High-risk OCT characteristics include thin-cap fibroatheroma, lipid arc >180°, macrophages, and minimum luminal area <3.5 mm². [58]D These findings identify plaque vulnerability rather than proving that every such lesion will cause AMI; long-term studies evaluated their association with subsequent cardiovascular events. [58]D[202]
Plaque burden and composition also influence risk. In SCOT-HEART and ISCHEMIA analyses, coronary CT angiography quantified total, calcified, noncalcified, and low-attenuation plaque, as well as plaque distribution and morphology; greater or more adverse plaque characteristics were investigated as predictors of fatal or nonfatal MI and cardiovascular death or MI. [33][34][35] A radiomic analysis of SCOT-HEART further examined patient-level plaque phenotypes to improve prediction of future MI beyond conventional attenuation-based plaque measurements. [34] In symptomatic patients, artificial-intelligence-guided quantitative CT assessed percent atheroma volume and whether lipid-lowering medication modified long-term outcomes, including death, MI, and unstable angina. [194]
Diabetes mellitus is associated with a more extensive and adverse coronary plaque phenotype. In SCOT-HEART, investigators compared coronary calcium, stenosis, adverse plaque characteristics, and quantitative calcified, noncalcified, low-attenuation, and total plaque burden in patients with and without diabetes. [33] Plaque composition may also affect outcomes after PCI: the ILUMIEN IV substudy specifically evaluated whether preprocedural predominant plaque morphology was associated with target-vessel failure after intervention. [230]
Plaque erosion, inflammation, and thrombogenicity
AMI may occur through plaque erosion, in which thrombus forms over an injured or dysfunctional endothelial surface without the same morphologic pattern as plaque rupture. The JAK2 V617F mutation, a form of clonal hematopoiesis of indeterminate potential (CHIP), was specifically investigated in relation to plaque erosion and rupture; accompanying experimental work implicated neutrophils in erosion associated with this mutation. [198] In patients with STEMI, CHIP was studied in relation to culprit-lesion morphology and major adverse cardiovascular events, with mutation burden assessed using variant-allele-frequency thresholds of >0.5%, >1%, and >2%. [54]D
Inflammation may promote plaque instability and thrombosis. Oxidized low-density lipoprotein is implicated in inflammatory atherosclerosis through the lectin-like oxidized LDL receptor-1 (LOX-1); a randomized phase 2 trial tested the LOX-1 antagonist MEDI6570 in patients with prior MI and residual inflammation, defined as high-sensitivity C-reactive protein ≥1 mg/L, using noncalcified plaque volume as the primary imaging endpoint. [32] These data support LOX-1-related inflammation as a biologically plausible contributor, but the trial’s primary plaque-volume endpoint was not significant. [32]
Coronary calcification is another marker of plaque biology. In STEMI, circulating and regional matrix Gla protein were evaluated in relation to OCT-detected plaque calcification and adverse outcomes, indicating that calcific plaque phenotype and calcification-related biology may contribute to prognosis. [193] Sepsis may intensify this process: a reported case demonstrated neutrophilic coronary endarteritis, plaque erosion, multiple coronary thrombi, and in-stent thrombosis over neoatherosclerosis, suggesting that sepsis-associated vascular inflammation can produce diffuse endothelial injury and plaque instability. [231]C
Nonatherosclerotic coronary causes
SCAD is an uncommon but important cause of AMI, particularly in younger women, and can involve the left main coronary artery. A pooled analysis of 132 reported patients with left-main SCAD found a predominantly female population with a mean age of approximately 40 years. [31] In contemporary STEMI cohorts undergoing primary PCI, SCAD has been associated with higher inpatient mortality, longer hospitalization, and greater hospitalization costs than non-SCAD STEMI. [197] Cardiogenic shock substantially worsens the clinical context and outcomes of SCAD; a systematic review and meta-analysis compared patients with SCAD complicated by shock with those without shock. [201]
Coronary vasospasm can cause transient or sustained coronary occlusion and AMI. Vasospastic angina is particularly prevalent in East Asian populations, and a genome-wide association study investigated RNF213 variants as genetic contributors to vasospastic angina and fatal MI risk. [199]
Triggering factors
Potential short-term triggers include nocturnal hypoxemia and sleep-disordered breathing. In patients with MI enrolled in the OSA-ACS project, investigators examined whether obstructive sleep apnea and nocturnal hypoxemia were associated with the timing of MI onset during the night. [195] The study used patient-reported onset of chest pain and an overnight type III sleep study after clinical stabilization. [195]
Iatrogenic myocardial injury is a separate mechanism. In patients with NSTE-ACS undergoing PCI, preprocedural CCTA plaque characteristics—including lipid-core, fibrous, and calcified components defined by CT attenuation thresholds of <30 HU, 30–350 HU, and ≥350 HU, respectively—were evaluated as predictors of periprocedural MI. [196] Thus, plaque composition may influence both spontaneous coronary events and procedural embolization or vessel injury. [196]
Summary
The principal etiologic pathway remains thrombogenic coronary atherosclerosis, but AMI can also result from erosion, inflammatory plaque destabilization, SCAD, vasospasm, infectious coronary injury, or procedure-related complications. Diabetes, overall plaque burden, adverse plaque morphology, CHIP—particularly JAK2 V617F—coronary calcification, residual inflammation, sleep-related hypoxemia, and cardiogenic shock in SCAD are clinically relevant modifiers or contexts identified in the cited evidence. [33][34][35][54]D[58]D[193][195][198][199][201][231]C
| Mechanism or modifier | Supporting evidence |
|---|---|
| Vulnerable atherosclerotic plaque | OCT and CCTA identify lipidic, calcific, fibrotic, low-attenuation, and radiomic plaque phenotypes associated with clinical risk assessment. [230][34][35] |
| Plaque erosion or rupture | JAK2 V617F and CHIP were studied in relation to erosion, rupture, culprit morphology, and adverse outcomes. [54]D[198] |
| Inflammatory destabilization | LOX-1/oxidized LDL biology, residual inflammation, and sepsis-related neutrophilic endarteritis provide mechanistic evidence. [32][231]C |
| SCAD | SCAD, including left-main SCAD, is an uncommon nonatherosclerotic cause of AMI and may be complicated by shock. [31][197][201] |
| Vasospasm | Vasospastic angina and RNF213 variants have been associated with risk of fatal MI. [199] |
| Procedural injury | CCTA plaque composition has been evaluated as a predictor of periprocedural MI in NSTE-ACS undergoing PCI. [196] |
Differential Diagnosis
- ▸An elevated cTn concentration alone does not distinguish AMI from other myocardial-injury states; serial change and objective evidence of ischemia are essential. [68][233]
- ▸In the cited AF/MI cohort, all participants had admission total cTnT **≥14 ng/L**, and long cTnT was investigated to improve etiologic discrimination. [68]
- ▸AAS and ATAAD can present with ischemic ECG changes and an initial suspicion of MI; missed diagnosis is associated with potentially dangerous delays. [232][75]
- ▸Aortic dissection, PE, and PTTM should be considered in patients with disproportionate dyspnea, right-heart failure, pulmonary hypertension, shock, or atypical chest pain. [71][232][241]
- ▸TTS, myocarditis, and anterior STEMI may overlap clinically and on echocardiography; CMR, strain analysis, and selected echocardiographic indices are investigational adjuncts. [74][236]
- ▸Hyperkalemia is a potentially lethal STEMI mimic capable of producing anteroseptal and inferior ST-segment elevations. [65]
- ▸Chronic myocardial injury has been operationalized as elevated cTn with sequential variation of **≤20%**, although short-interval application requires caution. [233]
- ▸MINOCA is heterogeneous and requires angiographic confirmation plus evaluation for its underlying mechanism. [239]
Acute myocardial infarction (AMI) should be distinguished from other causes of chest pain, ischemic electrocardiographic (ECG) changes, ventricular dysfunction, and elevated cardiac troponin (cTn). The diagnosis cannot be established from an elevated cTn concentration alone because cTn is detected in myocardial injury and in several non-infarction syndromes. [68]D A structured assessment should integrate symptoms, serial ECGs, the pattern of cTn change, echocardiography or cardiac magnetic resonance (CMR), and targeted testing for immediately life-threatening alternatives. [68]D[233]
Acute aortic syndrome and aortic dissection
Acute aortic syndrome (AAS), particularly acute Stanford type A aortic dissection (ATAAD), is a critical AMI mimic and may present with ischemic ECG changes or an initial clinical suspicion of MI. [232] In a retrospective study of 630,275 emergency-department visits, missed AAS diagnoses were evaluated against cases recognized during the initial visit, emphasizing that apparently coronary presentations can conceal AAS. [232] Acute aortic dissection and NSTEMI may share chest pain, dyspnea, and palpitations, and their distinction is essential because diagnostic and treatment pathways differ. [241]D Undertriage of aortic dissection has also been studied alongside STEMI and subarachnoid hemorrhage because triage decisions may delay care for high-risk conditions. [75]D
Potentially useful approaches include cross-sectional aortic imaging and biomarker-based discrimination. A case-control investigation identified differentially expressed peripheral-leukocyte mRNAs in ATAAD and subsequently evaluated their discrimination from AMI, but the evidence remains exploratory. [69]D A machine-learning model using clinical and laboratory variables was developed in 193 patients with aortic dissection and 160 with NSTEMI; its clinical value was assessed with decision-curve analysis, but external validation and routine clinical applicability require confirmation. [241]D Aortic dissection must be considered before antithrombotic or reperfusion treatment when the history, examination, ECG, or hemodynamics are atypical for uncomplicated AMI. [232][75]D
Pulmonary embolism and pulmonary vascular emergencies
Pulmonary embolism (PE) can cause chest symptoms, dyspnea, ECG abnormalities, right-heart strain, hemodynamic collapse, and cTn elevation, thereby mimicking AMI. The cited AAS study specifically notes the use of high-sensitivity troponin and D-dimer pathways for ACS and PE, while examining whether these strategies reduce missed AAS. [232] Acute right-heart failure with pulmonary hypertension and shock should also raise consideration of pulmonary tumor thrombotic microangiopathy (PTTM), a rare, rapidly progressive, and frequently post-mortem-diagnosed complication associated with known or occult adenocarcinoma. [71]D In an eight-patient retrospective series, PTTM presented as unclear sudden cardiac death or acute right-heart failure and was described as potentially treatable but usually fatal. [71]D
Atrial fibrillation, tachyarrhythmia, and myocardial injury without MI
Elevated cTn is frequent in patients presenting with atrial fibrillation or atrial flutter but is seldom caused by MI. [68]D The conventional high-sensitivity cTnT assay measures intact and highly fragmented cTnT, collectively termed total cTnT, and therefore detects myocardial injury without distinguishing its cause. [68]D The SuperTROPO study included 521 patients with AF alone and 188 with MI alone, including 139 with type 1 MI, all with admission total cTnT ≥14 ng/L; it investigated intact and long cTnT as a possible discriminator. [68]D These findings support interpreting cTn in the context of rhythm, rate, symptoms, ECG evolution, and serial kinetics rather than labeling every tachyarrhythmia-associated elevation as AMI. [68]D
Chronic myocardial injury and non-ischemic cTn elevation
Persistently elevated cTn may reflect chronic myocardial injury or underlying cardiac disease rather than acute infarction. [233] In a prospective multicenter suspected-ACS cohort, cTnT was measured at presentation and at 1, 2, and 6–36 hours, with diagnoses adjudicated using the Fourth Universal Definition of MI. [233] Chronic myocardial injury was defined as elevated cTn values varying by ≤20% on sequential measurements; the study assessed whether this criterion remains reliable when applied over short intervals in accelerated diagnostic pathways. [233] A small or absent serial change therefore argues against acute dynamic injury but does not, by itself, exclude AMI when clinical or imaging evidence of ischemia is present. [233]
Takotsubo syndrome and myocarditis
Takotsubo syndrome (TTS) and anterior STEMI with apical involvement can have overlapping symptoms and echocardiographic findings. [236] A retrospective study of 50 patients with confirmed TTS and 50 with AMI evaluated two echocardiographic indices—the inferior-apex ratio (IAR) and inferolateral-apex ratio (ILAR)—as bedside tools for distinguishing typical TTS from anterior STEMI; segmental strain and interobserver reproducibility were also assessed. [236] TTS may cause severe acute left-ventricular dysfunction and, in some patients, cardiogenic shock requiring mechanical support; a national retrospective analysis evaluated ECMO-associated outcomes in TTS with cardiogenic shock. [238]
CMR-based differentiation is also being investigated. A multicenter study analyzed 130 patients with TTS, AMI, or acute myocarditis and developed interpretable machine-learning models using CMR and clinical variables; right-ventricular strain was identified as a key feature under evaluation. [74]D These approaches are adjunctive and do not replace urgent coronary evaluation when STEMI is suspected. [74]D[236]
ECG mimics and other coronary phenotypes
Hyperkalemia can produce striking ST-segment elevations and neurological or muscular symptoms that resemble STEMI. [65]C A reported patient with anteroseptal and inferior ST elevations ultimately had neither stroke nor ACS, but a potentially lethal electrolyte disorder. [65]C ECG interpretation is therefore central, yet recognition of STEMI equivalents and mimics may be challenging; a 2026 survey of 62 emergency medical officers assessed knowledge in these areas. [234]
MINOCA is not a single alternative diagnosis but a heterogeneous AMI phenotype requiring angiographic confirmation of non-obstructive coronary arteries and further etiologic evaluation. [239] A retrospective cohort used clinical data, imaging, and laboratory variables with LASSO and multivariable modeling to develop a non-invasive MINOCA-identification algorithm. [239] Experimental biomarkers—including cTn composition, exosomal microRNAs, DNA-damage-response genes, and combinations of NT-proBNP and galectin-3 with machine learning—have shown investigational potential for differentiating MI, MI subtypes, or myocardial injury, but they are not established replacements for standard clinical adjudication. [70]D[72]D[73]D[240]
Practical diagnostic principle
The most dangerous errors arise when ischemic ECG changes or elevated cTn are treated as synonymous with type 1 AMI. AAS, PE, PTTM, tachyarrhythmia-related injury, chronic myocardial injury, TTS, myocarditis, hyperkalemia, and MINOCA-related mechanisms should be actively assessed according to the presenting phenotype and hemodynamic risk. [68]D[71]D[74]D[232][233]
| Differential diagnosis | Relevant evidence and diagnostic focus |
|---|---|
| Acute aortic syndrome/ATAAD | May present with ischemic ECG changes or suspected MI; consider urgent aortic imaging and avoid assuming coronary occlusion. [69]D[232] |
| Pulmonary embolism | May overlap with ACS pathways using cTn and D-dimer; assess pulmonary and right-heart findings. [232] |
| PTTM | Rare, rapidly progressive pulmonary hypertension and right-heart failure, often with occult adenocarcinoma. [71]D |
| AF/atrial flutter-related injury | cTn elevation is common but seldom due to MI; interpret total and serial cTn with rhythm and clinical context. [68]D |
| Chronic myocardial injury | Elevated cTn with sequential variation ≤20% may indicate chronic injury rather than acute dynamic injury. [233] |
| TTS or myocarditis | Can mimic AMI; echocardiography, strain, and CMR may assist. [74]D[236] |
| Hyperkalemia | Can produce marked ST elevation and neurological or muscular symptoms without ACS. [65]C |
| MINOCA | AMI with non-obstructive arteries is heterogeneous and requires etiologic evaluation after angiography. [239] |
Supportive Care and Complication Management
- ▸Transfusion decisions in MI with anemia must balance possible reduction in 30-day death or recurrent MI against possible heart-failure risk; use clinical context alongside hemoglobin. [243]
- ▸VA occurred in 3.9% of patients in a prospective AMI cohort, and low free triiodothyronine was investigated as a possible risk marker. [101]
- ▸AF risk may be informed by routine admission variables, glycemic variability, and the timing of AF onset, but these tools require clinical validation. [245][251][252]
- ▸Shock care requires rapid assessment for cardiac arrest, acute kidney injury, and need for renal replacement therapy or mechanical circulatory support. [246][250]
- ▸Evidence comparing Impella, intra-aortic balloon pump, and ECMO strategies remains largely observational and confounded by treatment selection. [12][247][253][254]
- ▸Preclinical findings on neuroinflammation, exercise, and immune-stromal remodeling are not yet human treatment recommendations. [256][257][258]
Principles of supportive care
Supportive management after acute myocardial infarction (AMI) should be individualized according to infarct type, hemodynamic status, anemia, renal function, arrhythmia risk, heart-failure risk, and the occurrence of cardiac arrest or cardiogenic shock. The available updated evidence is predominantly observational or predictive; therefore, these studies should complement, rather than replace, established reperfusion, monitoring, and guideline-directed management pathways. [243][245][246][248][250][252][253]C
Anemia and transfusion
In patients hospitalized with MI and anemia, the transfusion decision requires balancing a possible reduction in 30-day death or recurrent MI against a possible increase in heart failure. The MINT trial post hoc Bayesian analysis specifically estimated posterior risk differences and the probability that a liberal strategy reduced death or MI compared with a restrictive strategy, while also considering heart-failure risk. [243] This evidence supports reassessing hemoglobin, ischemic symptoms, hemodynamics, bleeding, and congestion rather than applying a transfusion strategy without clinical context. [243]
Arrhythmia surveillance and management
Ventricular arrhythmia (VA) remains an important in-hospital complication. In a prospective multicenter cohort of 3,277 patients with AMI, 123 patients (3.9%) developed VA during hospitalization; lower free triiodothyronine was investigated as a potential marker of VA risk. [101] A separate AMI cohort developed a mortality-prediction model incorporating electrophysiologic features, including fragmented QRS and electrical storm, together with metabolic and clinical variables; this model is intended for risk stratification, not as a substitute for immediate treatment of unstable arrhythmia. [255]
Atrial fibrillation (AF) is also common after AMI and is associated with adverse prognosis. A cross-cohort machine-learning study used routine, non-electrocardiographic variables available at cardiac intensive care unit admission to predict AF among patients admitted in sinus rhythm, with development and cross-national validation in Italian and Finnish cohorts. [245] Glycemic variability was evaluated in 10,439 patients in the MIMIC-IV database and was associated with AF and in-hospital mortality in analyses that included both White and non-White patients. [251] AF timing may be clinically relevant: a cohort of 3,390 patients compared early AF during the index hospitalization, late AF after discharge, and no AF, separately considering STEMI and NSTEMI. [252]
Continuous implantable monitoring after MI should be interpreted cautiously. In the unblinded BIO|GUARD-MI trial, an interim analysis identified more noncardiovascular adverse events in the monitoring group, leading to premature termination; secondary analyses examined participant-initiated contacts as a possible source of performance bias. [244] These findings emphasize that detected events and healthcare contacts can be influenced by knowledge of treatment allocation and should be considered when interpreting monitoring-trial outcomes. [244]
Heart failure, shock, and mechanical support
Acute heart failure can occur despite emergency PCI. A retrospective study evaluated triglyceride-glucose-related indices as markers of insulin resistance in relation to in-hospital acute heart failure after emergency PCI for AMI, supporting investigation of these indices as possible risk-identification tools rather than established treatment targets. [111]D Long-term outcomes in patients with CKD and AMI were examined in a prospective cohort comparing matched PCI and non-PCI groups, with all-cause mortality, new-onset heart failure, and CKD progression as outcomes. [248]
Cardiogenic shock complicating STEMI requires immediate coronary angiography and PCI when appropriate, together with escalation to specialized shock care. In a two-center study of 345 STEMI patients with shock, outcomes were compared among patients without cardiac arrest, with out-of-hospital cardiac arrest, and with in-hospital cardiac arrest. [246] In patients with AMI-related shock, acute kidney injury is a major determinant of prognosis; a 1,431-patient multicenter registry study developed and internally validated a LASSO-based nomogram to predict the need for renal replacement therapy. [250]
Temporary mechanical circulatory support should be selected according to phenotype, timing, ventricular failure, complications, and local expertise. A MIMIC-IV cohort compared initial intra-aortic balloon pump and Impella strategies when support was initiated within 24 hours of intensive-care admission for AMI with shock; because this was a retrospective database study, treatment selection and confounding limit causal interpretation. [253]C In patients with AMI-related shock undergoing PCI supported by veno-arterial ECMO, a propensity-matched analysis evaluated concomitant intra-aortic balloon pump support, particularly in relation to potential ECMO-related left-ventricular overload. [254] Retrospective data also examined Impella use in Killip class IV AMI complicated by pulseless VT or VF, with 30-day mortality as the primary endpoint. [247]
Microaxial-flow-pump experience extends beyond AMI. A multicenter retrospective analysis compared AMI-related and nonischemic shock among patients treated with Impella CP or 5-series devices, using 180-day all-cause mortality as the primary outcome. [12]D Durable ventricular assist-device implantation after AMI was examined in 335 EUROMACS registry patients; most had severe shock, and the median interval from AMI hospitalization to implantation was 9 days. [249]C These data describe highly selected rescue populations and should not be interpreted as evidence for routine device use. [12]D[247][249]C
Renal, metabolic, and recovery considerations
Patients with AMI and shock require serial assessment of renal function, urine output, acid-base status, perfusion, and fluid balance, with early nephrology and shock-team involvement when renal replacement therapy is likely. The available prediction model may help identify patients at risk for in-hospital renal replacement therapy but requires external validation. [250] Glycemic variability may identify patients at increased risk of AF or death, although observational associations do not establish that aggressive glucose manipulation improves outcomes. [251]
Experimental studies suggest that post-MI recovery is influenced by neuroinflammation, immune-stromal signaling, fibrosis, and electrophysiologic remodeling. Rat studies implicated hypothalamic microglial interferon-regulatory factor 5 in neuroinflammation during heart-failure progression and found that exercise training altered post-MI scar electrophysiology. [256]D[257]D A review described bidirectional interactions among immune and stromal cells during cardiac repair and fibrosis. [258]D These findings are mechanistic and preclinical; they do not yet define human supportive-care protocols. [256]D[257]D[258]D
Special populations and prognosis
SCAD complicated by cardiogenic shock appears to represent a distinct high-risk phenotype. A systematic review of four studies found that patients with SCAD and shock were less likely to be female or have a prior MI than those without shock, although the evidence base was limited. [201] CKD, cardiac arrest, VA, AF, acute heart failure, and shock should therefore prompt intensified monitoring and multidisciplinary reassessment, while recognizing that most newer studies are retrospective and primarily prognostic. [101][111]D[201][245][246][248][251][252][255]
Practical evidence boundaries
The strongest directly relevant evidence in this update concerns transfusion strategy after MI and anemia. [243] Most other findings are cohort studies, prediction models, registry analyses, systematic reviews of few studies, or preclinical investigations; they identify risk patterns and generate hypotheses but do not independently establish treatment thresholds. [12]D[101][111]D[201][244][245][246][247][248][249]C[250][251][252][253]C[254][255][256]D[257]D[258]D
| Complication or setting | Evidence-informed consideration | Evidence limitation |
|---|---|---|
| MI with anemia | Compare liberal and restrictive transfusion strategies while weighing 30-day death or MI against heart failure. [243] | Post hoc Bayesian analysis; clinical context remains essential. [243] |
| Ventricular arrhythmia | Monitor closely; VA occurred in 3.9% of a prospective AMI cohort. [101] | FT3 association and prediction models do not establish treatment thresholds. [101][255] |
| Atrial fibrillation | Consider admission risk factors, glycemic variability, and early versus late timing. [245][251][252] | Mostly retrospective or predictive evidence. [245][251][252] |
| Cardiogenic shock | Evaluate cardiac arrest phenotype, renal injury, and need for renal replacement therapy. [246][250] | Registry and prediction-model evidence. [246][250] |
| Mechanical support | Individualize Impella, IABP, or VA-ECMO decisions; selected studies assessed support within 24 hours and 180-day mortality. [12]D[253]C[254] | No randomized comparison in the cited studies. [12]D[253]C[254] |
Prognosis and Long-term Outcomes
- ▸Physiology-guided complete revascularization is beneficial in older patients (≥75 years) regardless of frailty or diabetes status.
- ▸Stress Hyperglycemia Ratio (SHR) and TyG index are key metabolic predictors of mortality.
- ▸Severe obesity (BMI ≥35) combined with inflammation (CRP ≥2 mg/L) significantly worsens long-term NSTEMI prognosis.
- ▸Malnutrition (CONUT score 5-12) independently predicts poor outcomes in elderly STEMI patients.
- ▸Regional cardiogenic shock networks and optimized mechanical circulatory support escalation improve survival in refractory shock.
- ▸Machine learning models utilizing routine clinical data or CT-derived body composition provide robust 1-year to 10-year risk stratification.
The prognosis following acute myocardial infarction (AMI) is determined by a complex interplay of physiological, metabolic, and systemic factors. Modern risk stratification has evolved to incorporate machine learning, physiological flow assessments, and comprehensive frailty evaluations to better predict long-term mortality and major adverse cardiovascular events (MACE).
Revascularization and Physiological Assessment
In older patients (≥75 years) with AMI and multivessel disease, physiology-guided complete revascularization has demonstrated consistent benefits. Data from the FIRE trial indicate that this strategy reduces the risk of a composite endpoint (death, MI, stroke, or ischemia-driven revascularization) across the entire spectrum of frailty, from fit to frail (Clinical Frailty Scale 1–9) [121]. Furthermore, the presence of diabetes mellitus does not attenuate the benefits of physiology-guided complete revascularization in this elderly population [205]. For frail older patients specifically with NSTEMI, the SENIOR-RITA trial suggests that while they experience higher MACE rates, the comparative benefit of an invasive versus conservative strategy remains a subject of ongoing investigation [203]. In patients undergoing transcatheter aortic valve replacement (TAVR) with concomitant coronary artery disease, percutaneous coronary intervention (PCI) reduces MACE regardless of frailty status [204].
Post-procedural physiological assessment is a critical prognostic marker. The residual global Murray law-based angiographic quantitative flow ratio (μQFR), calculated as the sum of post-procedural μQFR in treated vessels and pre-procedural values in non-treated vessels, is a significant predictor of long-term outcomes in patients with acute coronary syndrome (ACS) [120].
Metabolic and Inflammatory Risk Factors
Metabolic dysregulation significantly impacts AMI outcomes. The Stress Hyperglycemia Ratio (SHR), which reflects acute glycemic stress relative to chronic control, shows a dose-response relationship with in-hospital mortality [209]. Similarly, the triglyceride-glucose (TyG) index is associated with increased risk of AMI and all-cause mortality in patients with coronary artery disease [206]. In diabetic AMI patients, admission-based models using routine variables can effectively characterize risk heterogeneity for 180-day mortality [210]. Interestingly, in NSTEMI patients undergoing PCI, a higher hemoglobin glycation index (HGI) has been associated with more favorable survival over a median follow-up of 60 months [186].
Inflammation and body composition also play pivotal roles. In critically ill NSTEMI patients, the combination of severe obesity (BMI ≥35 kg/m²) and elevated C-reactive protein (CRP ≥2 mg/L) is associated with significantly higher in-hospital and 10-year all-cause mortality [179]C. Additionally, plasma levels of soluble low-density lipoprotein receptor (sLDLR) have emerged as a prospective marker for MI and cardiovascular mortality [208].
Frailty, Malnutrition, and Psychosocial Factors
Frailty and nutritional status are potent predictors of adverse outcomes in elderly STEMI patients. Malnutrition, as assessed by the Controlling Nutritional Status (CONUT) score (scores 5–12), is linked to poor in-hospital and 1-year outcomes, even when adjusted for frailty [215]. Psychosocial factors also influence recovery; in patients with comorbid major depressive disorder (MDD) and STEMI, the use of selective serotonin reuptake inhibitors (SSRIs) prior to the event is associated with improved survival outcomes at 1 month, 1 year, and 3 years [213].
Cardiogenic Shock and Advanced Support
For patients presenting with cardiogenic shock (CS), structured regional hub-and-spoke networks improve in-hospital mortality through standardized care and early advanced support [217]. In cases of severe CS requiring venoarterial extracorporeal membrane oxygenation (V-A ECMO), preadmission β-blocker use has been associated with weaning failure [214]. For patients bridged to a durable left ventricular assist device (dLVAD), escalating from partial-support to full-support microaxial flow pumps (mAFP) may improve circulatory preconditioning and outcomes [216]C.
Advanced Predictive Modeling
Machine learning (ML) and novel imaging metrics are refining prognostic accuracy. Echocardiographic grading systems (Grades 1–4) reflecting the severity of myocardial injury can stratify long-term mortality risk after a first-time STEMI, with a median follow-up of 5.5 years [207]. ML multiorgan analysis of coronary CT angiography, incorporating body composition data, provides prognostic information for 10-year mortality and MI risk [211]. Furthermore, interpretable ML models using routine laboratory and demographic data have been validated to predict 1-year cardiac death following PCI with high accuracy [212]C. For secondary prevention of ischemic events, novel agents like the factor XI inhibitor asundexian are being evaluated to reduce recurrent stroke risk, which remains a significant concern post-ACS [140].
| Marker | Population | Outcome Association |
|---|---|---|
| SHR | General AMI | Dose-response increase in in-hospital mortality [209] |
| TyG Index | CAD/AMI | Increased all-cause mortality [206] |
| CONUT Score (5-12) | Elderly STEMI | Higher 1-year mortality and in-hospital complications [215] |
| BMI ≥35 + CRP ≥2 | Critically ill NSTEMI | Increased 10-year all-cause mortality [179]C |
| Residual μQFR | ACS post-PCI | Predictor of long-term MACE [120] |
| SSRI Use | STEMI + Depression | Improved 3-year survival [213] |
Special Populations
- ▸Extended DAPT (24 months) reduces ischemic events in patients with multivessel disease who remain event-free at 12 months.
- ▸The combination of high HbA1c and elevated microvascular resistance (AMR) predicts poor outcomes in diabetic STEMI.
- ▸Severe obesity and CRP >2 mg/L jointly increase long-term mortality in critically ill NSTEMI patients.
- ▸Sleep disorders in COPD patients are significantly associated with increased risks of heart failure and MI.
- ▸Serum albumin ≤3.6 g/dL is a predictor of MACE in elderly patients with atrial fibrillation.
- ▸Acute-phase IL-6 and SAA levels post-COVID-19 are linked to cardiovascular events for up to six years.
Multivessel Coronary Artery Disease
Patients with multivessel coronary artery disease (MVD) represent a high-risk subgroup following acute myocardial infarction (AMI). Recent evidence suggests that extending dual antiplatelet therapy (DAPT) beyond the standard 12-month period may be beneficial for event-free patients who have undergone drug-eluting stent (DES) implantation [218]. In a randomized trial of patients aged 18 to 75, an additional 12 months of DAPT (aspirin plus clopidogrel) significantly reduced the composite risk of cardiovascular death and nonfatal myocardial infarction compared to aspirin monotherapy [218].
Diabetes Mellitus and Metabolic Dysfunction
Diabetes mellitus (DM) significantly complicates the prognosis of AMI. Risk heterogeneity within this population is high, and admission-based models utilizing routine variables have been developed to predict 180-day mortality with performance comparable to the GRACE score [210]. In patients with diabetic ST-segment elevation myocardial infarction (STEMI), the combination of elevated angiography-derived microvascular resistance (AMR) and high HbA1c levels serves as a potent joint predictor of major adverse cardiovascular and cerebrovascular events (MACCEs) [178].
Furthermore, the triglyceride-glucose (TyG) index has emerged as a critical marker; higher TyG index levels are independently associated with an increased risk of AMI and all-cause mortality in patients with coronary artery disease [206]. Interestingly, in patients with non-ST-segment elevation myocardial infarction (NSTEMI) undergoing percutaneous coronary intervention (PCI), the hemoglobin glycation index (HGI) has shown a complex relationship with outcomes, where higher HGI was associated with more favorable survival over a 60-month follow-up in specific cohorts [186].
Obesity and Inflammation
In critically ill NSTEMI patients, the interplay between body mass index (BMI) and systemic inflammation is a major determinant of survival. Severe obesity combined with elevated C-reactive protein (CRP) levels (dichotomized at 2 mg/L) significantly increases both in-hospital and 10-year all-cause mortality [179]C. This highlights the necessity of integrating inflammatory markers like CRP into the risk stratification of obese patients [179]C.
MINOCA and Takotsubo Syndrome
Patients diagnosed with myocardial infarction with nonobstructive coronary arteries (MINOCA) or Takotsubo syndrome (TS) often experience significant psychological distress. Internet-delivered cognitive behavioral therapy (iCBT) has been evaluated as a non-pharmacological intervention to address elevated symptoms of stress (Perceived Stress Scale ≥25) and anxiety (HADS-A ≥8) in these populations [220].
Chronic Obstructive Pulmonary Disease (COPD)
Patients with comorbid COPD and sleep disorders face a heightened risk of adverse cardiovascular outcomes. Data from the UK Biobank indicates that sleep disturbances in COPD patients contribute to increased risks of stroke, heart failure, and myocardial infarction, likely mediated by chronic intermittent hypoxia and systemic inflammation [222].
The Elderly and Arrhythmias
In elderly patients with non-valvular atrial fibrillation (AF), serum albumin (SA) levels serve as a prognostic indicator. Patients with SA ≤3.6 g/dL have a higher incidence of MACE, including non-fatal MI and cardiovascular death [227]. Additionally, new-onset atrial fibrillation (NOAF) following major surgeries like esophagectomy is associated with adverse cardiovascular complications over a 12-month period [225].
Post-COVID-19 Cardiovascular Risk
Long-term cardiovascular vulnerability following COVID-19 infection is increasingly recognized. Elevated acute-phase inflammatory markers, specifically Interleukin-6 (IL-6) and serum amyloid A (SAA), are associated with an increased risk of incident myocardial infarction and all-cause mortality up to six years post-infection [229].
| Population | Marker/Threshold | Clinical Implication |
|---|---|---|
| Multivessel CAD | DAPT >12 months | Reduced CV death and Re-MI [218] |
| Diabetic STEMI | AMR + HbA1c | Predicts MACCE post-revascularization [178] |
| NSTEMI (Critically Ill) | BMI + CRP >2 mg/L | Increased 10-year mortality [179]C |
| Elderly (AF) | Albumin ≤3.6 g/dL | Higher risk of MACE [227] |
| Post-COVID-19 | IL-6 and SAA | Long-term (6-year) CV risk [229] |
Guidelines and Resources
- ▸The 2025 ACC/AHA guideline provides a unified framework for all Acute Coronary Syndromes, replacing separate STEMI and NSTEMI documents.
- ▸High-sensitivity troponin H0/H1 algorithms allow for rapid triage in up to 75% of emergency department patients.
- ▸Radial access and drug-eluting stents are the preferred standards for primary PCI.
- ▸DAPT duration is now individualized (1–36 months) based on ischemic vs. bleeding risk scores.
- ▸Oxygen therapy is only indicated if oxygen saturation falls below 90%.
- ▸Intravascular imaging is increasingly recommended to guide PCI procedures.
The management of acute myocardial infarction (AMI) is governed by evolving international guidelines that integrate advancements in diagnostic speed, revascularization techniques, and pharmacotherapy. The 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline represents a major consolidation, retiring previous separate documents for STEMI (2013) and NSTEMI (2014) to provide a unified approach to Acute Coronary Syndromes (ACS) [153].
Diagnostic Algorithms and Imaging
Modern diagnostic strategies emphasize the use of high-sensitivity cardiac troponins (hs-cTn) as the first-line biochemical marker [157]. The European Society of Cardiology (ESC) recommends a rapid 0-hour/1-hour algorithm for ruling in or ruling out AMI, which allows approximately 75% of emergency patients to be triaged early [157][169]. However, this 1-hour rule is not applicable to patients who present very early after the onset of chest pain [157]. For stable ischemic heart disease, guidelines emphasize a structured approach to diagnosis using clinical history and risk stratification [159].
Imaging plays a critical role in both diagnosis and procedural guidance. Radionuclide imaging, including gated myocardial perfusion scintigraphy and PET, is validated for determining right and left ventricular ejection fractions (LVEF) and volumes [162]. Echocardiography remains the cornerstone for identifying cardiac sources of embolism, which account for 15–30% of ischemic strokes [170]. During percutaneous coronary intervention (PCI), the 2023 ESC and 2024 CVIT expert consensus documents suggest that intravascular imaging should be considered to guide the procedure (Class II recommendation) [154].
Revascularization and Procedural Standards
Primary PCI is the preferred reperfusion strategy for STEMI [154][164]. Current standards favor the radial artery as the primary access site and the use of drug-eluting stents (DES) over bare-metal stents [164]. Routine thrombus aspiration is no longer recommended [164]. For patients with multivessel disease, complete revascularization during the index hospitalization is now advised [164]. In the setting of cardiogenic shock, the SCAI classification system (Stages A–E) provides a multidisciplinary framework for categorizing the severity of the disease state, which has seen stagnant mortality rates for 30 years despite mechanical support options [156].
Pharmacotherapy and Antithrombotic Management
Dual antiplatelet therapy (DAPT) remains a cornerstone of post-AMI care. The duration of DAPT is increasingly individualized based on a balance of ischemic versus bleeding risks, with durations ranging from 1 to 36 months [168]. Potent P2Y12 inhibitors like prasugrel and ticagrelor are often preferred over clopidogrel in the ACS setting [165]. For periprocedural anticoagulation, bivalirudin has been downgraded in recent updates [164]. Oxygen therapy is specifically reserved for patients with an oxygen saturation <90% [164]. Beta-blockers should be used with caution in the acute phase due to the risk of provoking cardiogenic shock [163].
Pre-hospital and Emergency Care
Pre-hospital management focuses on rapid assessment and transfer by emergency medical services (EMS) [158]. While patients presenting during 'off-hours' may have higher risk profiles and receive less aggressive initial treatment, studies have indicated that their short-term outcomes are not necessarily worse than those presenting during regular hours [166]. During the COVID-19 pandemic, specific protocols were established to manage AMI while minimizing viral exposure, recognizing that COVID-19 can cause complex cardiovascular manifestations including myocarditis simulating AMI [155].
| Year | Organization | Focus | Key Change |
|---|---|---|---|
| 2025 | ACC/AHA/ACEP | Unified ACS | Retires 2013 STEMI and 2014 NSTEMI guidelines [153] |
| 2024 | CVIT | Primary PCI | Emphasis on intravascular imaging guidance [154] |
| 2019 | SCAI | Cardiogenic Shock | New A-E staging system for shock severity [156] |
| 2017 | ESC | STEMI | Radial access preference; complete revascularization [164] |
| 2015 | ESC | NSTEMI | Introduction of 1-hour troponin algorithm [169] |
References
- [1]
Di Fusco SA, Matteucci A, Alonzo A et al.. “Beta-Blocker Therapy After Myocardial Infarction: A Systematic Review and Meta-Analysis of Contemporary Randomized Controlled Trials.” International journal of molecular sciences (2026). PMID: 41828582 ↗
L1aSR_MA_RCTCited in: Definition, Synonyms, and Classification - [2]
Yang Y, Liao M, Liu X et al.. “Prognostic Impact of Renin-Angiotensin System Inhibitors in Revascularized Patients with Acute Myocardial Infarction and Preserved or Mildly Reduced Ejection Fraction: A Retrospective Cohort Study.” Journal of clinical medicine (2026). PMID: 41976977 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [3]
Smidtslund P, Harjutsalo V, Thorn V et al.. “Comparison of incidence patterns and risk profiles of ST-elevation and non-ST-elevation myocardial infarction in type 1 diabetes in Finland: a nationwide cohort study.” The lancet. Diabetes & endocrinology (2026). PMID: 41871591 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification, Special Populations - [4]
Kryeziu B, Poniku A, Henein MY et al.. “Epidemiological 11-Year Dynamics Study of Acute Myocardial Infarction: A Cohort Study in a Country with a Transitional Healthcare System.” Global heart (2026). PMID: 41766718 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [5]
Lu G, Wang X, Wang X et al.. “Case Report: Rapid progression of inflammation-driven coronary artery lesions in a normolipidemic patient with ANCA-associated vasculitis complicated by Stanford type A aortic dissection.” Frontiers in immunology (2026). PMID: 41909680 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification - [6]
Khalaf Y, Atta S, Helal A et al.. “Survival Beyond the Odds: Twelve-Week Follow-Up After Conservative Management of Post-Infarction Ventricular Free Wall Rupture.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026). PMID: 41772389 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification - [7]
Vural A, Dolanbay T, Cumaoglu MO et al.. “Metabolic risk factors associated with premature myocardial infarction in adults ≤ 35 years: a case-control study.” BMC cardiovascular disorders (2026). PMID: 41776422 ↗
L3bCASE_CONTROLCited in: Definition, Synonyms, and Classification - [8]
Madandar E, Zarinfar Y, Namazi MH et al.. “Associations of Endothelial-Related lncRNAs with Early-Onset STEMI: A Case-Control Study.” Journal of cardiovascular translational research (2026). PMID: 41758284 ↗
L3bCASE_CONTROLCited in: Definition, Synonyms, and Classification - [9]
Chen S, Wang R, Ma J et al.. “Impact of a Prehospital Chest Pain Alert App-Mediated Prehospital-in-Hospital Coordination Model on Treatment Delays and Clinical Outcomes in Patients With ST-Elevation Myocardial Infarction: Protocol for a 4-Year Retrospective Real-World Cohort Study.” JMIR research protocols (2026). PMID: 41973638 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification, Prognosis and Long-term Outcomes, Special Populations - [10]
Zhang Y, Wang S, Fang Z et al.. “Predictive Performance of Serum Monomeric C-Reactive Protein for Major Adverse Cardiovascular Events in Patients With Acute ST-Segment Elevation Myocardial Infarction at One-Year Post-Discharge: A Retrospective Cohort Study.” British journal of hospital medicine (London, England : 2005) (2026). PMID: 41914002 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification, Special Populations - [11]
Zhao J, Hong H, Fanaroff A et al.. “Advancing In-Hospital Mortality Prediction for Acute Myocardial Infarction: an analysis from the American Heart Association Get-With-the-Guidelines Coronary Artery Disease Registry.” American heart journal (2026). PMID: 41990900 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [12]
Ughetto A, Schrage B, Fürholz M et al.. “Beyond the STEMI Paradigm: Expanding the Scope of microAxial Flow Pump in Cardiogenic Shock.” The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2026). PMID: 41966345 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [13]
Speckauskiene V, Meilutyte-Lukauskiene D, Cerapaite-Trusinskiene R et al.. “Prognostic utility of Killip classification in acute myocardial infarction: a retrospective cohort analysis in contemporary clinical practice.” European heart journal open (2026). PMID: 41958748 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [14]
Aleksova A, Janjusevic M, Marketou M et al.. “Charting individualized pathways: IGF-1 and vitamin D in guiding personalized medicine for residual risk after AMI.” Progress in cardiovascular diseases (2026). PMID: 41956273 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [15]
Graves JM, Waken RJ, Wang F et al.. “Acute Myocardial Infarction in Medicare Beneficiaries During and After the COVID-19 Pandemic.” JAMA network open (2026). PMID: 41920542 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Special Populations - [16]
Kim CH, Joh HS, Kim HK et al.. “Comparison of Clinical Outcomes Between Incomplete and Complete Revascularization in NSTEMI Patients With Multivessel Disease.” JACC. Asia (2026). PMID: 41920117 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [17]
Laffan J, Gao H, Street A et al.. “Outcomes according to timely or delayed primary percutaneous coronary intervention or fibrinolysis in a national registry of patients with ST-segment elevation myocardial infarction.” Open heart (2026). PMID: 41916670 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Prognosis and Long-term Outcomes, Special Populations - [18]
Lugo-Gavidia LM, Saucedo JF, Arias-Mendoza A et al.. “Implementing the GWTG-CAD Program in Mexico: Feasibility, Challenges and Lessons Learned for Acute and Secondary Prevention and Management.” Journal of the American Heart Association (2026). PMID: 41914361 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Special Populations - [19]
Zhao Y, Chen XY, Zhu GJ et al.. “Incremental prognostic value of left atrial strain for heart failure-related events following ST-Segment elevation myocardial infarction.” European journal of radiology (2026). PMID: 41894993 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Supportive Care and Complication Management, Prognosis and Long-term Outcomes, Special Populations - [20]
Pozzessere P, Di Lauro M, Incantalupo F et al.. “Evaluating the Efficacy of CPS, HEART and TIMI Score in Emergency Department Patients with Non-Traumatic Chest Pain: A Pilot Study.” Medical sciences (Basel, Switzerland) (2026). PMID: 41892866 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Special Populations - [21]
Beske RP, Klein A, Jensen LO et al.. “Early clinical recovery in STEMI cardiogenic shock: insights from the DanGer shock trial.” European heart journal. Acute cardiovascular care (2026). PMID: 41873805 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [22]
Palmisano T, Bilchick K, Guarraia D. “Hemoglobin A1c is more predictive of type 1 myocardial infarction than low-density lipoprotein or body mass index.” Nutrition, metabolism, and cardiovascular diseases : NMCD (2026). PMID: 41864779 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [23]
Sharkey SW, Herman R, Witt DR et al.. “Performance of Artificial Intelligence-Powered ECG Analysis in Suspected ST-Segment Elevation Myocardial Infarction.” JACC. Advances (2026). PMID: 41863986 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [24]
Bilato C, Girardi G, Zuin M et al.. “Temporal trend in epidemiology and performance indicators of acute myocardial infarction: A 25 years population-based study.” International journal of cardiology (2026). PMID: 41861850 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [25]
Mavridis A, Viktorisson A, Leósdóttir M et al.. “Medication adherence after myocardial infarction: Predictors, mortality and cardiovascular outcomes.” Atherosclerosis (2026). PMID: 41856699 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Prognosis and Long-term Outcomes - [26]
Hu D, Wu D, Huang T et al.. “Monocyte-to-lymphocyte ratio as a predictor of left ventricular aneurysm in acute STEMI patients.” Frontiers in endocrinology (2025). PMID: 41847671 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [27]
Ahmadi-Beni M, Mokhtarian K, Mobini GR et al.. “Fasciola hepatica-Derived Proteins Shield the Heart From Type 2 Myocardial Infarction in Rats by Modulating Oxidative Stress and Inflammatory Imbalance: Insights Relevant to the Hygiene Hypothesis.” Oxidative medicine and cellular longevity (2026). PMID: 41823333 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [28]
Möser C, Prystupa K, Schön M et al.. “Cohort profile: The DIabetes and ST-segment Elevation Myocardial Infarction (DISTEMI) Study.” Cardiovascular diabetology (2026). PMID: 41821026 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [29]
Kuku KO, Lenselink C, Venema CS et al.. “Impact of Coronary Artery Disease Extent on GRACE Risk Score Prognostic Performance After ST-Segment-Elevation Myocardial Infarction.” Journal of the American Heart Association (2026). PMID: 41804884 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Prognosis and Long-term Outcomes - [30]
Zhang YK, Shao X, Hu ST et al.. “Development and Validation of a Prognostic Model for One-year Mortality in Older Adults with Acute Myocardial Infarction Incorporating Activities of Daily Living Impairment.” Clinical interventions in aging (2026). PMID: 41799377 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Prognosis and Long-term Outcomes - [31]
Morosato M, Gaspardone C, Romagnolo D et al.. “Left Main Spontaneous Coronary Artery Dissection: Clinical Features, Management, and Outcomes.” JACC. Cardiovascular interventions (2025). PMID: 40208153 ↗
L2aSR_OBSCited in: Etiology and Triggering Factors - [32]
O'Donoghue ML, Morrow DA, Vavere AL et al.. “Antibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a randomized phase 2 trial.” Nature medicine (2025). PMID: 40999229 ↗
L1bRCTCited in: Etiology and Triggering Factors - [33]
Gebert ZM, Kwiecinski J, Weir-McCall JR et al.. “Impact of diabetes mellitus on coronary artery plaque characteristics and outcomes in the SCOT-HEART trial.” Journal of cardiovascular computed tomography (2025). PMID: 39788814 ↗
L1bRCTCited in: Etiology and Triggering Factors - [34]
Kolossváry M, Lin A, Kwiecinski J et al.. “Coronary Plaque Radiomic Phenotypes Predict Fatal or Nonfatal Myocardial Infarction: Analysis of the SCOT-HEART Trial.” JACC. Cardiovascular imaging (2025). PMID: 39480364 ↗
L1bRCTCited in: Etiology and Triggering Factors - [35]
Nurmohamed NS, Min JK, Anthopolos R et al.. “Atherosclerosis quantification and cardiovascular risk: the ISCHEMIA trial.” European heart journal (2024). PMID: 39101625 ↗
L1bRCTCited in: Etiology and Triggering Factors - [36]
Rexhaj E, Bär S, Soria R et al.. “Effects of alirocumab on endothelial function and coronary atherosclerosis in myocardial infarction: A PACMAN-AMI randomized clinical trial substudy.” Atherosclerosis (2024). PMID: 38513436 ↗
L1bRCTCited in: Etiology and Triggering Factors - [37]
Hong XL, Loh YH, Li DB et al.. “Intracoronary administration of tenecteplase to prevent PCI-related myocardial infarction in patients with echo-attenuated coronary plaques: study protocol for a multicenter, prospective, randomized controlled trial.” Trials (2024). PMID: 39587685 ↗
L2bTRIAL_NONRANDOMCited in: Etiology and Triggering Factors - [38]
Zhao J, Chen Z, Yang J et al.. “Effect of KLF15-Mediated Circadian Rhythm on Myocardial Infarction: A Narrative Review.” International journal of molecular sciences (2025). PMID: 40429972 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [39]
Chaturvedi A, Gadela NV, Kalra K et al.. “Non-atherosclerotic coronary causes of myocardial infarction in women.” Progress in cardiovascular diseases (2025). PMID: 39880182 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [40]
Chapman AR, Taggart C, Boeddinghaus J et al.. “Type 2 myocardial infarction: challenges in diagnosis and treatment.” European heart journal (2025). PMID: 39658094 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [41]
Juhasz V, Charlier FT, Zhao TX et al.. “Targeting the adaptive immune continuum in atherosclerosis and post-MI injury.” Atherosclerosis (2024). PMID: 39546915 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [42]
Młynarska E, Czarnik W, Fularski P et al.. “From Atherosclerotic Plaque to Myocardial Infarction-The Leading Cause of Coronary Artery Occlusion.” International journal of molecular sciences (2024). PMID: 39000400 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [43]
Katz AE, Gupte T, Ganesh SK. “From Atherosclerosis to Spontaneous Coronary Artery Dissection: Defining a Clinical and Genetic Risk Spectrum for Myocardial Infarction.” Current atherosclerosis reports (2024). PMID: 38761354 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [44]
Schelemei P, Wagner E, Picard FSR et al.. “Macrophage mediators and mechanisms in cardiovascular disease.” FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2024). PMID: 38275140 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [45]
Wang W, Huang B. “Recurrent Chest Pain Due to Spontaneous Coronary Artery Dissection Diagnosed by Optical Coherence Tomography.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2025). PMID: 41077821 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [46]
Mori T, Aoyama H, Tanaka A et al.. “Detailed Visualization of the Dissected False Lumen Using Intravascular Ultrasound, Optical Coherence Tomography, and Angioscopy in a Young Man With Acute Myocardial Infarction Caused by Spontaneous Coronary Artery Dissection.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2025). PMID: 40437848 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [47]
Mumma BE, Kim JM, Rogers JH. “Chest Pain in the Setting of Acute Stress: A Tale of Two Women.” Clinical therapeutics (2024). PMID: 39578136 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors, Differential Diagnosis - [48]
Littmann L. “An unusual cause of giant T waves.” The American journal of emergency medicine (2024). PMID: 38839488 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [49]
Cojocaru PA, Țieranu ML, Piorescu MTL et al.. “Myocardical Infarction in Young Adults: Revisiting Risk Factors and Atherothrombotic Pathways.” Medicina (Kaunas, Lithuania) (2025). PMID: 41011006 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [50]
Imbesi A, Greco A, Capodanno D. “Anti-inflammatory strategies for patients with atherosclerotic coronary disease.” Expert review of cardiovascular therapy (2025). PMID: 40968010 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [51]
Sharpe EE, Rose CH, Tweet MS. “Obstetric anesthesia considerations in pregnancy-associated myocardial infarction: a focused review.” International journal of obstetric anesthesia (2024). PMID: 39227292 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [52]
McAlister C, Kang M, Alfadhel M et al.. “Thrombolysis in Spontaneous Coronary Artery Dissection-Angiographic Findings and Clinical Outcomes.” The Canadian journal of cardiology (2026). PMID: 41173456 ↗
L5OTHERCited in: Etiology and Triggering Factors - [53]
Geers J, Manral N, Park C et al.. “AI-quantified epicardial adipose tissue and prediction of future myocardial infarction in patients with cardiometabolic disease: a post-hoc analysis from the SCOT-HEART trial.” Cardiovascular diabetology (2025). PMID: 41126192 ↗
L5OTHERCited in: Etiology and Triggering Factors - [54]
Li J, Chen R, Zhou J et al.. “Effect of clonal hematopoiesis on plaque morphology and prognosis in patients with acute myocardial infarction.” Genome medicine (2025). PMID: 40855342 ↗
L5OTHERCited in: Etiology and Triggering Factors - [55]
Raphael CE, Sandoval Y, Beachey JD et al.. “Causes of Myocardial Infarction in Younger Patients: Troponin-Elevation in Persons ≤65 Years Old in Olmsted County.” Journal of the American College of Cardiology (2025). PMID: 40864006 ↗
L5OTHERCited in: Etiology and Triggering Factors - [56]
Stepanian A, Travers RJ, Tesfu A et al.. “Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke.” Circulation (2025). PMID: 40762051 ↗
L5OTHERCited in: Etiology and Triggering Factors - [57]
Sun Q, Wang S, Zeng M et al.. “Impact of Carrying DNMT3A or TET2 Mutations on Plaque Characteristics and Prognosis in Patients With STEMI Based on OCT.” Circulation. Cardiovascular imaging (2025). PMID: 40755316 ↗
L5OTHERCited in: Etiology and Triggering Factors - [58]
Biccirè FG, Fabbiocchi F, Gatto L et al.. “Long-Term Prognostic Impact of OCT-Derived High-Risk Plaque Features: Extended Follow-Up of the CLIMA Study.” JACC. Cardiovascular interventions (2025). PMID: 40500004 ↗
L5OTHERCited in: Etiology and Triggering Factors - [59]
Hirose T, Fujii K, Hashimoto K et al.. “Plaque rupture and calcified nodules: major contributors to out-of-hospital cardiac arrest in acute myocardial infarction.” Cardiovascular intervention and therapeutics (2025). PMID: 40478392 ↗
L5OTHERCited in: Etiology and Triggering Factors - [60]
Xu C, Yang ML, Kho PF et al.. “Cross-Ancestry Associations of Spontaneous Coronary Artery Dissection Genetic Risk With Coronary Atherosclerosis and Migraine Headache.” Journal of the American Heart Association (2025). PMID: 40357661 ↗
L5OTHERCited in: Etiology and Triggering Factors - [61]
Giangiacomi F, Popelier B, Lochy S et al.. “OPENing a new ECLECTIC approach to NSTEMI and cardiac arrest using ECG-less coronary computed tomography angiography. Study design and rationale of two prospective clinical studies.” Cardiovascular revascularization medicine : including molecular interventions (2026). PMID: 41314866 ↗
L2bTRIAL_NONRANDOMCited in: Differential Diagnosis - [62]
Raat W, Nees L, Vaes B. “Diagnostic accuracy of signs and symptoms in acute coronary syndrome and acute myocardial infarction.” Scandinavian journal of primary health care (2025). PMID: 39308022 ↗
L2aSR_OBSCited in: Differential Diagnosis - [63]
Kharawala A, Nagraj S, Setia G et al.. “Cardiac Critical Care of the Cardio-Obstetric Patient.” Journal of intensive care medicine (2026). PMID: 39819322 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [64]
Ricci F, Martini C, Scordo DM et al.. “ECG Patterns of Occlusion Myocardial Infarction: A Narrative Review.” Annals of emergency medicine (2025). PMID: 39818676 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [65]
Gamboa S, Shenvi C. “The great imitator: Hyperkalemia presenting with paralysis and ST segment elevations.” The American journal of emergency medicine (2026). PMID: 41274182 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [66]
Di Leo M, Vasumini N, Maida A et al.. “Cardiac magnetic resonance imaging in myocardial infarction with non-obstructive coronary arteries (MINOCA): current and evolving perspectives.” Expert review of cardiovascular therapy (2025). PMID: 41103008 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [67]
Ceriani E, Berra S, Agozzino F et al.. “ST-segment elevation in acute pericarditis and myocardial involvement: electrocardiographic and clinical profiling.” Open heart (2026). PMID: 41850763 ↗
L5OTHERCited in: Differential Diagnosis - [68]
Airaksinen KEJ, Teppo K, Vasankari T et al.. “Long Troponin T to Separate Troponin Elevations Among Patients With Atrial Fibrillation Versus Myocardial Infarction.” Journal of the American Heart Association (2026). PMID: 41757465 ↗
L5OTHERCited in: Differential Diagnosis - [69]
Zhou Y, Chen C, Li J et al.. “Identification and Validation of Differentially Expressed mRNAs From Peripheral Leukocytes for Acute Stanford Type A Aortic Dissection.” Journal of the American Heart Association (2025). PMID: 41378480 ↗
L5OTHERCited in: Differential Diagnosis - [70]
Li L, Liu Y, Wu Y et al.. “Comparison of the cardiac troponin I-cardiac troponin T-troponin C complex and cardiac troponin I and T in distinguishing myocardial infarction using a single sample at presentation.” Clinical chemistry and laboratory medicine (2026). PMID: 41213158 ↗
L5OTHERCited in: Differential Diagnosis - [71]
Andreß S, Melnic R, Christow H et al.. “Right-sided cardiogenic shock from acute pulmonary tumor thrombotic microangiopathy: a rare but deadly cardio-oncologic and metabolic emergency.” Clinical research in cardiology : official journal of the German Cardiac Society (2026). PMID: 40954305 ↗
L5OTHERCited in: Differential Diagnosis - [72]
Zhou P, Zhang J, Wu X et al.. “Differential diagnosis of acute myocardial infarction based on plasma Exosomal MicroRNA.” International journal of legal medicine (2026). PMID: 40850945 ↗
L5OTHERCited in: Differential Diagnosis - [73]
Snavely A, Jackson L, Hunter CJ et al.. “Differentiating Type 1 and Type 2 myocardial infarction using a machine learning algorithm and biomarkers.” The American journal of emergency medicine (2025). PMID: 40834835 ↗
L5OTHERCited in: Differential Diagnosis - [74]
Du Z, Hu H, Shen C et al.. “Right Ventricular Strain as a Key Feature in Interpretable Machine Learning for Identification of Takotsubo Syndrome: A Multicenter CMR-based Study.” Academic radiology (2025). PMID: 40404506 ↗
L5OTHERCited in: Differential Diagnosis - [75]
Sax DR, Warton EM, Mark DG et al.. “Emergency Department Triage Accuracy and Delays in Care for High-Risk Conditions.” JAMA network open (2025). PMID: 40314952 ↗
L5OTHERCited in: Differential Diagnosis - [76]
Yildiz M, Pico M, Henry TD et al.. “Sex Differences in Patients Presenting With ST-Segment Elevation Myocardial Infarction and Nonobstructive Coronary Arteries.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2025). PMID: 39906977 ↗
L5OTHERCited in: Differential Diagnosis - [77]
Wang L, Wu H, Wu C et al.. “A deep-learning system integrating electrocardiograms and laboratory indicators for diagnosing acute aortic dissection and acute myocardial infarction.” International journal of cardiology (2025). PMID: 39880045 ↗
L5OTHERCited in: Differential Diagnosis - [78]
Li L, Liu Y, Katrukha IA et al.. “Characterization of Cardiac Troponin Fragment Composition Reveals Potential for Differentiating Etiologies of Myocardial Injury.” Clinical chemistry (2025). PMID: 39697116 ↗
L5OTHERCited in: Differential Diagnosis - [79]
Araoz PA, Gadam S, Bhanushali AK et al.. “Triple Rule Out CT in the Emergency Department: Clinical Risk and Outcomes (Triple Rule Out in the Emergency Department).” Academic radiology (2025). PMID: 39658473 ↗
L5OTHERCited in: Differential Diagnosis - [80]
Airaksinen JKE, Tuominen T, Paana T et al.. “Novel troponin fragmentation assay to discriminate between Takotsubo syndrome and acute myocardial infarction.” European heart journal. Acute cardiovascular care (2024). PMID: 39422200 ↗
L5OTHERCited in: Differential Diagnosis - [81]
Son JH, Park JK, Bang JH et al.. “Exosomal miRNAs Differentiate Chronic Total Occlusion from Acute Myocardial Infarction.” International journal of molecular sciences (2024). PMID: 39337705 ↗
L5OTHERCited in: Differential Diagnosis - [82]
Seitz A, Dicpinigaitis AJ, Zhang C et al.. “Ischemic events are infrequent in patients with ovarian hyperstimulation syndrome.” Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (2025). PMID: 39321946 ↗
L5OTHERCited in: Differential Diagnosis - [83]
Yakovlev S, Gvozdeva A. “Left Ventricular Pericardial Strangulation: A Diagnostic Challenge in Acute Coronary Syndrome.” Methodist DeBakey cardiovascular journal (2026). PMID: 41725857 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [84]
Bui-Thi HD, Vu VH, Nguyen KD et al.. “Successful management of protracted anaphylaxis-induced severe acute respiratory distress syndrome masquerading as non-ST elevation myocardial infarction: a rare case report.” BMC cardiovascular disorders (2026). PMID: 41606487 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [85]
Dewi IP, Damayanti KR, Anggitama AM et al.. “Tackling the ST elevation in leptospirosis: A double-edged sword between bleeding and thrombosis - A case report.” Narra J (2025). PMID: 40951499 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [86]
Lacaita PG, Feuchtner GM. “Ruptured coronary aneurysm with fatal bleeding: a tricky differential diagnosis.” The international journal of cardiovascular imaging (2025). PMID: 40261595 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [87]
Ying HL, Zhao H, Zhang C et al.. “Pitfalls of computed tomography angiography examination in veno-arterial extracorporeal membrane oxygenation patients: a case report of a patient with cardiac rupture.” Journal of cardiothoracic surgery (2024). PMID: 39736763 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [88]
Raizner AE. “Myocardial Infarction with Normal Coronary Arteries.” Methodist DeBakey cardiovascular journal (2024). PMID: 39525371 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [89]
Gao S, An R, Wang C. “Tracheopericardial fistula in lung cancer masquerading as acute myocardial infarction: a case report.” BMC pulmonary medicine (2024). PMID: 39449137 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [90]
Haberman D, Verma B, Abusnina W et al.. “Low- Versus High-capacity Impella for CS After AMI: A Systematic Review and Pooled Data Analysis.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026). PMID: 41507087 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [91]
Parlow S, Jung RG, Almoosawy SA et al.. “Prognostic Factors Among Patients Receiving Microaxial Flow Pump for Acute Myocardial Infarction-Related Cardiogenic Shock: A Systematic Review and Meta-Analysis.” Critical care medicine (2026). PMID: 41504526 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [92]
Scquizzato T, Grunau B, Fernando SM et al.. “Temporary mechanical circulatory support after return of spontaneous circulation following cardiac arrest: a systematic review and meta-analysis.” Resuscitation (2025). PMID: 41232590 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [93]
Obradovic D, Schulz L, Loncar G et al.. “Prognostic performance of cardiogenic shock 4 proteins prediction model in infarct-related cardiogenic shock.” ESC heart failure (2026). PMID: 41711227 ↗
L1bRCTCited in: Supportive Care and Complication Management, Prognosis and Long-term Outcomes - [94]
Sørensen R, Møller JE, Vandenbriele C et al.. “Bleeding in Patients With Infarct-Related Cardiogenic Shock: A DanGer Shock Substudy.” JACC. Cardiovascular interventions (2026). PMID: 41672689 ↗
L1bRCTCited in: Supportive Care and Complication Management, Prognosis and Long-term Outcomes - [95]
Jensen LO, Beske RP, Eiskjær H et al.. “Delay From First Symptoms in Patients Presenting With STEMI and Cardiogenic Shock: Insights From the DanGer Shock Trial.” Circulation. Cardiovascular interventions (2026). PMID: 41521915 ↗
L1bRCTCited in: Supportive Care and Complication Management - [96]
Kim MC, Ahn JH, Hyun DY et al.. “Complete revascularization timing in ST-segment elevation myocardial infarction and multivessel disease with heart failure: the OPTION-STEMI trial.” European heart journal (2026). PMID: 41493330 ↗
L1bRCTCited in: Supportive Care and Complication Management - [97]
Mangner N, Beske RP, Hassager C et al.. “Sex-Specific Microaxial Flow Pump Use and Outcomes in Infarct-Related Cardiogenic Shock in the DanGer Shock Trial.” Journal of the American College of Cardiology (2026). PMID: 41222528 ↗
L1bRCTCited in: Supportive Care and Complication Management - [98]
Nijveldt R, Maeng M, Beijnink CWH et al.. “Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction.” The New England journal of medicine (2026). PMID: 41159879 ↗
L1bRCTCited in: Supportive Care and Complication Management - [99]
Laborante R, Paglianiti DA, Elia S et al.. “Safety and efficacy of early initiation of mineralocorticoid receptor antagonist after an acute decompensated heart failure event or acute myocardial infarction with cardiac dysfunction: a meta-analysis of randomized clinical trials.” ESC heart failure (2026). PMID: 41712413 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [100]
Sheng Z, Chen B. “Differences in the characteristics and outcomes of STEMI versus NSTEMI cardiogenic shock: A systematic review and meta-analysis.” Medicine (2025). PMID: 41189239 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [101]
Deng L, Gao Y, Pan L et al.. “Free Triiodothyronine as a Biomarker for Ventricular Arrhythmia Following Myocardial Infarction: A Multicenter Prospective Cohort Study.” Clinical interventions in aging (2026). PMID: 41867325 ↗
L2bCOHORTCited in: Supportive Care and Complication Management, Special Populations - [102]
Israeli Hadar Y, Haim M, Tsaban G et al.. “Impact of late ventricular fibrillation on postdischarge 1-year mortality of patients presenting with acute myocardial infarction: a nationwide retrospective study.” BMJ open (2025). PMID: 41469077 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [103]
Kloosterman M, Smits KC, Stoks J et al.. “Computer-aided characterization of the arrhythmogenic substrate after myocardial infarction.” Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2026). PMID: 41512109 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [104]
Thiele H, Hassager C. “Cardiogenic Shock.” The New England journal of medicine (2026). PMID: 41467651 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [105]
Marcos-Garcés V, Bertolín-Boronat C, Merenciano-González H et al.. “Left Ventricular Remodeling After Myocardial Infarction-Pathophysiology, Diagnostic Approach and Management During Cardiac Rehabilitation.” International journal of molecular sciences (2025). PMID: 41303447 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [106]
Spaeth LD, Rahim M, Kochar A et al.. “Cardiogenic Shock and Temporary Mechanical Circulatory Support.” The Medical clinics of North America (2025). PMID: 41136064 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [107]
Boettger P, Preusse-Sondermann H, Sedighi J et al.. “Acute kidney injury as a prognostic determinant in cardiogenic shock: a cohort study.” Clinical and experimental nephrology (2026). PMID: 41225284 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [108]
Hassan AM, Aziz F, Tripolt NJ et al.. “Carbohydrate antigen 125 (CA125) following acute myocardial infarction: effects of empagliflozin and association with heart failure readouts in the EMMY trial.” Scientific reports (2025). PMID: 41430429 ↗
L1bRCTCited in: Supportive Care and Complication Management - [109]
Filipescu R, Collins SP, Radu RI et al.. “Therapeutic Advances in the Management of Cardiogenic Shock.” American journal of therapeutics (Unknown). PMID: 41543923 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [110]
Adi A, Jain R, Guru S et al.. “Antimicrobial Use in Acute Myocardial Infarction-Related Cardiogenic Shock.” Journal of the American Heart Association (2026). PMID: 41904804 ↗
L5OTHERCited in: Supportive Care and Complication Management, Prognosis and Long-term Outcomes, Special Populations - [111]
Feng R, Hu L, Zhu Y et al.. “Association between TyG-related indices and in-hospital acute heart failure in patients with acute myocardial infarction after emergency percutaneous coronary intervention.” Frontiers in endocrinology (2026). PMID: 41869030 ↗
L5OTHERCited in: Supportive Care and Complication Management - [112]
Smyth D, Zhang L, Al-Khalaf M et al.. “Hematopoietic expression of cIAP2 drives inflammation and heart failure after myocardial infarction.” Nature cardiovascular research (2026). PMID: 41820671 ↗
L5OTHERCited in: Supportive Care and Complication Management - [113]
Wei Q, Zhou H, Sun J et al.. “SLC31A1 knockdown mitigates post-MI heart failure via regulation of copper metabolism.” Frontiers in immunology (2026). PMID: 41808820 ↗
L5OTHERCited in: Supportive Care and Complication Management - [114]
Wybraniec MT, Sufryd A, Cichoń M et al.. “Cardiogenic shock in the course of myocardial infarction: the results of the Shock-POL registry.” ESC heart failure (2026). PMID: 41746839 ↗
L5OTHERCited in: Supportive Care and Complication Management - [115]
Han T, Wen X, Guo Y et al.. “E3 ubiquitin ligase TRIM21-mediated K48-linked ubiquitination of ALDH2 rs671 mutant promotes adverse cardiac remodeling.” JCI insight (2026). PMID: 41734032 ↗
L5OTHERCited in: Supportive Care and Complication Management - [116]
Cheng M, Li L, Huang X et al.. “Linggui Zhugan Decoction mitigates post-myocardial infarction heart failure through modulation of cardiomyocyte F-actin cytoskeletal organization.” Phytomedicine : international journal of phytotherapy and phytopharmacology (2026). PMID: 41655544 ↗
L5OTHERCited in: Supportive Care and Complication Management - [117]
Zhou MM, Xu L, Huang DZ et al.. “KCNQ2 downregulation in left stellate ganglion neurons exacerbates malignant ventricular arrhythmias after myocardial infarction.” Journal of molecular and cellular cardiology (2026). PMID: 41654290 ↗
L5OTHERCited in: Supportive Care and Complication Management - [118]
Semedzhieva NE, Tsakova A, Lozanova V et al.. “17β-Estradiol Does Not Designate Non-Sex-Specific Early Ventricular Arrhythmia in Acute Myocardial Infarction, in Contrast to C-Reactive Protein.” International journal of molecular sciences (2026). PMID: 41596617 ↗
L5OTHERCited in: Supportive Care and Complication Management - [119]
Chiotis S, Giannopoulos G, Boulmpou A et al.. “Association of common risk factors with major adverse cardiac events and mortality in patients with MINOCA: A systematic review and meta-analysis.” International journal of cardiology (2026). PMID: 41655606 ↗
L2aSR_OBSCited in: Prognosis and Long-term Outcomes - [120]
Shen X, Zhang H, Li Z et al.. “Post-PCI Global QFR and Long-Term Outcomes in ACS: Findings From the FAVOR III China Trial.” JACC. Cardiovascular interventions (2026). PMID: 41986039 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes, Special Populations - [121]
Passo BD, Tonet E, Lanzilotti V et al.. “Consistent benefit of physiology-guided complete revascularization across the spectrum of frailty in older patients with myocardial infarction: a prespecified analysis of the FIRE trial.” Age and ageing (2026). PMID: 41965249 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes, Special Populations - [122]
Choi KH, Kang D, Kim W et al.. “Discontinuation of Beta-Blocker Therapy after Myocardial Infarction.” The New England journal of medicine (2026). PMID: 41910427 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes, Special Populations - [123]
Sans-Roselló J, Fernández-Peregrina E, Kuku KO et al.. “Timing of cardiogenic shock and clinical outcomes in takotsubo syndrome: A multicenter cohort study.” International journal of cardiology (2026). PMID: 41765143 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [124]
Madhavan MV, Gregson J, Redfors B et al.. “Spontaneous Myocardial Infarction After Left Main Revascularization: The EXCEL Trial.” Circulation (2026). PMID: 41664927 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes - [125]
Liu Y, Liu X, Sun D et al.. “Aspirin Combined With Ticagrelor or Clopidogrel in STEMI Patients With Diabetes Mellitus and Poor Glycemic Control Undergoing Primary PCI: A Multicenter Retrospective Cohort Study.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026). PMID: 41656976 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [126]
Heuts S, Pustjens TF, Lux Á et al.. “Probabilities of treatment effects in complete or culprit-only revascularization for NSTEMI: A Bayesian re-analysis of the SLIM trial.” American heart journal (2026). PMID: 41654213 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes - [127]
Zhao P, Li ZX, Jiang EL et al.. “Acute myocardial infarction following allogeneic hematopoietic stem cell transplantation: A national cohort study.” Cancer letters (2026). PMID: 41628833 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [128]
Huang DS, Fang CY, Hsueh SK et al.. “Predictors of Clinical Outcomes in Myocardial Infarction Patients Underwent Coronary Intervention With Rotational Atherectomy: A Single-Center Retrospective Study in Southern Taiwan.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026). PMID: 41623217 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [129]
Armstrong PW, Zheng Y, Welsh RC et al.. “Primary percutaneous coronary intervention within the first hour: Insights from early-treated patients with ST-elevation myocardial infarction.” American heart journal (2026). PMID: 41619999 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes - [130]
Wang B, Song Y, Fan Y et al.. “Association of Initial Laxative Strategy With Clinical Outcomes in Critically Ill Patients With Acute Myocardial Infarction: A Retrospective Cohort Study.” Cardiovascular therapeutics (2026). PMID: 41964389 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes, Special Populations - [131]
Zhou T, Yang K, Yang Y et al.. “Complete Blood Count-Derived Inflammation Indices to Predict 3-Year All-Cause Mortality in Patients With Diabetes and Acute Myocardial Infarction in Critical Care: Retrospective Cohort Study With Single-Center External Validation.” JMIR medical informatics (2026). PMID: 41818746 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes, Special Populations - [132]
Spadafora L, Bernardi M, Biondi-Zoccai G et al.. “GRACE score for risk stratification and completeness of revascularization in older patients with myocardial infarction.” Journal of cardiovascular medicine (Hagerstown, Md.) (2026). PMID: 41860766 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes, Special Populations - [133]
Zhao X, Chen R, Li J et al.. “Utility of Novel Lipid Parameters for Risk Stratification in Patients with Diabetes and STEMI-from a Prospective Study.” Vascular health and risk management (2026). PMID: 41877706 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes, Special Populations - [134]
Nyanga AF, Mohamed J, Msunza M et al.. “Performance of the Grace ACS Risk Score in Predicting in-Hospital and Six-Month Mortality in Patients with ACS: A Single Center Retrospective Cohort Study.” Vascular health and risk management (2026). PMID: 41736925 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [135]
Sundh J, Parker WAE, Oldgren J et al.. “Prognostic Value of Impaired Spirometry in Patients with Myocardial Infarction: A Longitudinal Study of Two European Cohorts.” International journal of chronic obstructive pulmonary disease (2026). PMID: 41947782 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes, Special Populations - [136]
Yarahmadi P, Hedlin H, Bates S et al.. “Survival After the First Myocardial Infarction in Older Women: A Prospective Cohort Analysis From the WHI.” Journal of the American Heart Association (2026). PMID: 41848053 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [137]
Dahiya G, Bohman JK, Tonna JE et al.. “Acid-Base Status During Venoarterial Extracorporeal Membrane Oxygenator Support in Patients With Cardiogenic Shock.” Journal of the American Heart Association (2026). PMID: 41823232 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [138]
Elbadawi A, Chen A, Wojdyla D et al.. “Contemporary Trends, Characteristics, and Outcomes of Patients Undergoing Percutaneous Coronary Intervention for Stent Thrombosis.” JACC. Cardiovascular interventions (2026). PMID: 41813273 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [139]
Kwon Y, Kim N, Kim DH et al.. “Long-Term Clinical Outcomes of Acute Myocardial Infarction Based on Institutional Experience With IVUS.” Journal of the American Heart Association (2026). PMID: 41757462 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [140]
Sharma M, Dong Q, Hirano T et al.. “Asundexian for Secondary Stroke Prevention.” The New England journal of medicine (2026). PMID: 41985132 ↗
L1bRCTCited in: Special Populations - [141]
Delewi R, Aarts HM, Broeze GM et al.. “Deferral of percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation (PRO-TAVI): an investigator-initiated, multicentre, open-label, non-inferiority, randomised controlled trial.” Lancet (London, England) (2026). PMID: 41921523 ↗
L1bRCTCited in: Special Populations - [142]
Kang J, Park S, Yang HM et al.. “Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention: 10-year follow-up of the HOST-EXAM trial.” Lancet (London, England) (2026). PMID: 41921522 ↗
L1bRCTCited in: Special Populations - [143]
Marcadenti A, Bersch-Ferreira AC, Vieira Machado RH et al.. “Supplementation with mixed nuts does not improve inflammatory biomarkers or dietary inflammatory potential in post-myocardial infarction: a secondary analysis of the DICA-NUTS trial.” Nutrition, metabolism, and cardiovascular diseases : NMCD (2026). PMID: 41856832 ↗
L1bRCTCited in: Special Populations - [144]
Sundqvist MO, Wärme J, Hjort M et al.. “Helicobacter pylori, Inflammation, and Long-Term Outcome in Patients With Acute Myocardial Infarction: A Prospective Cohort Study.” Helicobacter (2026). PMID: 41834132 ↗
L2bCOHORTCited in: Special Populations - [145]
Asadi N, Azarbarzin M, Salmani F. “The effect of early mobilization program on changes in hemodynamic symptoms in patients with acute myocardial infarction.” Journal of bodywork and movement therapies (2026). PMID: 41927220 ↗
L1bRCTCited in: Special Populations - [146]
Wang H, Chou E, Robinson RD et al.. “Federated Meta-Analysis of HEART Score Performance for Emergency Department Chest Pain.” Academic emergency medicine : official journal of the Society for Academic Emergency Medicine (2026). PMID: 41943236 ↗
L2aSR_OBSCited in: Special Populations - [147]
Turchin A, Shubina M, Morrison FJ et al.. “Cumulative excess weight exposure over time and cardiovascular risk: A prospective cohort study.” PloS one (2026). PMID: 41950162 ↗
L2bCOHORTCited in: Special Populations - [148]
Nesova A, Vorobeva D, Ryabov V. “Impact of the risk-treatment paradox on in-hospital and long-term outcomes in patients with very high-risk non-ST-elevation acute coronary syndrome.” The Indian journal of medical research (2026). PMID: 41934433 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [149]
Shen YC, Sarkar N, Hsia RY. “Community-Level Procedure Volume and Patient Health Profiles Following PCI-Capable Facility Openings.” JAMA network open (2026). PMID: 41910975 ↗
L5OTHERCited in: Special Populations - [150]
Cars T, Gustafsson S, Chan Q et al.. “Methodological Challenges of Emulating a Target Trial to Assess Effectiveness of Timing of PCSK9 Inhibitor Treatment Initiation Post Myocardial Infarction.” Pharmacoepidemiology and drug safety (2026). PMID: 41902372 ↗
L5OTHERCited in: Special Populations - [151]
Chen Y, Chang A, Cheng F et al.. “A nomogram for predicting in-hospital death in a multinational cohort of patients with takotsubo syndrome.” European journal of clinical investigation (2026). PMID: 41888991 ↗
L5OTHERCited in: Special Populations - [152]
Ozaki Y, Tobe A, Onuma Y et al.. “CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) in 2026.” Cardiovascular intervention and therapeutics (2026). PMID: 41749019 ↗
L1cGUIDELINECited in: Guidelines and Resources - [153]
Rao SV, O'Donoghue ML, Ruel M et al.. “2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Circulation (2025). PMID: 40014670 ↗
L1cGUIDELINECited in: Guidelines and Resources - [154]
Ozaki Y, Tobe A, Onuma Y et al.. “CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) in 2024.” Cardiovascular intervention and therapeutics (2024). PMID: 39302533 ↗
L1cGUIDELINECited in: Guidelines and Resources - [155]
Mahmud E, Dauerman HL, Welt FGP et al.. “Management of Acute Myocardial Infarction During the COVID-19 Pandemic: A Position Statement From the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP).” Journal of the American College of Cardiology (2020). PMID: 32330544 ↗
L1cGUIDELINECited in: Guidelines and Resources - [156]
Baran DA, Grines CL, Bailey S et al.. “SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2019). PMID: 31104355 ↗
L1cGUIDELINECited in: Guidelines and Resources - [157]
Charpentier S, Chenevier-Gobeaux C. “[2015 ESC guidelines: 1-hour rule-out and rule-in of acute myocardial infarction with high-sensitive troponin T].” Presse medicale (Paris, France : 1983) (2016). PMID: 27374265 ↗
L1cGUIDELINECited in: Guidelines and Resources - [158]
Beygui F, Castren M, Brunetti ND et al.. “Pre-hospital management of patients with chest pain and/or dyspnoea of cardiac origin. A position paper of the Acute Cardiovascular Care Association (ACCA) of the ESC.” European heart journal. Acute cardiovascular care (2020). PMID: 26315695 ↗
L1cGUIDELINECited in: Guidelines and Resources - [159]
Qaseem A, Fihn SD, Williams S et al.. “Diagnosis of stable ischemic heart disease: summary of a clinical practice guideline from the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons.” Annals of internal medicine (2012). PMID: 23165664 ↗
L1cGUIDELINECited in: Guidelines and Resources - [160]
George JC, Dangas GD. “2009 Focused updates to guidelines in ST-elevation myocardial infarction and percutaneous coronary intervention: application to interventional cardiology.” JACC. Cardiovascular interventions (2010). PMID: 20170887 ↗
L1cGUIDELINECited in: Guidelines and Resources - [161]
Pollack CV, Antman EM, Hollander JE. “2007 focused update to the ACC/AHA guidelines for the management of patients with ST-segment elevation myocardial infarction: implications for emergency department practice.” Annals of emergency medicine (2008). PMID: 18519158 ↗
L1cGUIDELINECited in: Guidelines and Resources - [162]
Hesse B, Lindhardt TB, Acampa W et al.. “EANM/ESC guidelines for radionuclide imaging of cardiac function.” European journal of nuclear medicine and molecular imaging (2008). PMID: 18224320 ↗
L1cGUIDELINECited in: Guidelines and Resources - [163]
Campbell-Scherer DL, Green LA. “ACC/AHA guideline update for the management of ST-segment elevation myocardial infarction.” American family physician (2009). PMID: 19530638 ↗
L1cGUIDELINECited in: Guidelines and Resources - [164]
Thiele H, Desch S, de Waha S. “[Acute myocardial infarction in patients with ST-segment elevation myocardial infarction : ESC guidelines 2017].” Herz (2017). PMID: 29119223 ↗
L1cGUIDELINECited in: Guidelines and Resources - [165]
Schäfer A, Bauersachs J. “[Focused update on dual antiplatelet treatment : ESC guidelines 2017].” Herz (2017). PMID: 29043405 ↗
L1cGUIDELINECited in: Guidelines and Resources - [166]
Pollack CV, Hollander JE, Chen AY et al.. “Non-ST-elevation myocardial infarction patients who present during off hours have higher risk profiles and are treated less aggressively, but their outcomes are not worse: a report from Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation of the ACC/AHA Guidelines CRUSADE initiative.” Critical pathways in cardiology (2009). PMID: 19258835 ↗
L1cGUIDELINECited in: Guidelines and Resources - [167]
. “[Guidelines of the American College of Cardiology/American Heart Association 2007 for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. Part VI].” Kardiologiia (2008). PMID: 18991825 ↗
L1cGUIDELINECited in: Guidelines and Resources - [168]
Massberg S, Polzin A. “[Update ESC-Guideline 2017: Dual Antiplatelet Therapy].” Deutsche medizinische Wochenschrift (1946) (2018). PMID: 30060279 ↗
L1cGUIDELINECited in: Guidelines and Resources - [169]
Hochholzer W, Neumann FJ. “[The new 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation].” Deutsche medizinische Wochenschrift (1946) (2016). PMID: 27254627 ↗
L1cGUIDELINECited in: Guidelines and Resources - [170]
Pepi M, Evangelista A, Nihoyannopoulos P et al.. “Recommendations for echocardiography use in the diagnosis and management of cardiac sources of embolism: European Association of Echocardiography (EAE) (a registered branch of the ESC).” European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology (2010). PMID: 20702884 ↗
L1cGUIDELINECited in: Guidelines and Resources - [171]
. “API expert consensus document on management of ischemic heart disease.” The Journal of the Association of Physicians of India (2006). PMID: 16909697 ↗
L1cGUIDELINECited in: Guidelines and Resources - [172]
Mahler SA, Ashburn NP, Villenthi A et al.. “Validation of a 0/2-Hour Point-Of-Care High Sensitivity Troponin Algorithm: A Multisite US Study.” Academic emergency medicine : official journal of the Society for Academic Emergency Medicine (2026). PMID: 42470147 ↗
L2bCited in: Definition, Synonyms, and Classification - [173]
Garrouste V, Guerineau A, Guenezan J et al.. “External Validation of the SCARE Score for Predicting Acute Myocardial Infarction in Patients Calling Emergency Medical Communication Centers: A Prospective Multicenter Study.” Prehospital emergency care (2026). PMID: 42213793 ↗
L2bCited in: Definition, Synonyms, and Classification - [174]
Alasmary MY, Almalki MJ, Almalki FH et al.. “Interleukin-6 Inhibition for Patients with Acute Myocardial Infarction: A Systematic Review and Meta-Analysis.” Saudi medical journal (2026). PMID: 42293710 ↗
L1aCited in: Definition, Synonyms, and Classification - [175]
Shlyakhover VE, Rozenbaum Z, Bruoha S. “Superimposed Takotsubo syndrome and acute myocardial infarction: a systematic review and pooled analysis of published cases.” International journal of cardiology. Heart & vasculature (2026). PMID: 42327959 ↗
L2aCited in: Definition, Synonyms, and Classification - [176]
Gupta MD, Kunal S, Girish MP et al.. “Comparison of ASCVD Risk Prediction Models in STEMI: Insights From a South Asian Cohort.” JACC. Asia (2026). PMID: 42470426 ↗
L3bCited in: Definition, Synonyms, and Classification - [177]
Mallol-Simmonds M, Rojas CG, Cañete Palta I et al.. “Depressive symptoms and health-related quality of life following acute myocardial infarction.” Frontiers in cardiovascular medicine (2026). PMID: 42445537 ↗
L3bCited in: Definition, Synonyms, and Classification - [178]
Gao S, Wang Y, Wang J et al.. “Elevated angiography-derived microvascular resistance and HbA1c levels jointly predict adverse outcomes in patients with diabetic STEMI: a multicenter retrospective cohort study.” Frontiers in endocrinology (2026). PMID: 42440617 ↗
L3bCited in: Definition, Synonyms, and Classification - [179]
Li Y, Wang Y, Lu P et al.. “Joint effects of severe obesity and inflammation on mortality in critically ill non-ST-segment elevation myocardial infarction patients: a cohort study with external validation.” Frontiers in endocrinology (2026). PMID: 42422429 ↗
L4Cited in: Definition, Synonyms, and Classification - [180]
Yu H, Qi S, Tian G. “The predictive value of NT-proBNP/ALB ratio for in-hospital pericardial effusion in young acute myocardial infarction patients.” Frontiers in cardiovascular medicine (2026). PMID: 42422178 ↗
L3bCited in: Definition, Synonyms, and Classification - [181]
Wrenn JO, Behrens M, Hershey MS et al.. “Large Language Model Summarization of Physician-to-Physician Calls for Interhospital Transfer of Patients With ST-Elevation Myocardial Infarction: Observational Study.” Journal of medical Internet research (2026). PMID: 42348906 ↗
L3bCited in: Definition, Synonyms, and Classification - [182]
Schwab M, Pamminger M, Kremser C et al.. “Association of Deep Learning-based Myocardial Infarction Size Quantification in Cardiac MRI with Cardiac Biomarker Levels.” Radiology. Cardiothoracic imaging (2026). PMID: 42347575 ↗
L3bCited in: Definition, Synonyms, and Classification - [183]
Yang Z, Liu Z, Xu Y et al.. “Serum LRG1 as a non-invasive biomarker for identifying complex coronary anatomy in pre-angiography risk stratification.” Frontiers in cardiovascular medicine (2026). PMID: 42338730 ↗
L3bCited in: Definition, Synonyms, and Classification - [184]
Wong HJ, Teo FJJ, Yau CE et al.. “Prognosis of patients with ST-elevation myocardial infarction presenting to the emergency department without chest pain: a retrospective nationwide cohort study.” Heart (British Cardiac Society) (2026). PMID: 42315345 ↗
L3bCited in: Definition, Synonyms, and Classification - [185]
Ninla-Aesong P, Sanakus S, Phonphet C et al.. “CBC-Derived Inflammatory Indices and Myocardial Injury Severity at Presentation in Acute Myocardial Infarction: Association and Discriminative Performance.” Journal of clinical medicine (2026). PMID: 42279258 ↗
L3bCited in: Definition, Synonyms, and Classification - [186]
Jiang H, Zhao Y, Zhao Y et al.. “Association between hemoglobin glycation index and all-cause mortality in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.” Frontiers in endocrinology (2026). PMID: 42267308 ↗
L3bCited in: Definition, Synonyms, and Classification - [187]
Chen BH, Li SL, Xiang JY et al.. “AI-based Histologic Heterogeneity of Microvascular Obstruction at Cardiac MRI for Predicting MACEs: A Multicenter Study.” Radiology (2026). PMID: 42227866 ↗
L3bCited in: Definition, Synonyms, and Classification - [188]
Mantilla Pérez B, Hurtado-Ortiz A, López J et al.. “Health-related quality of life after acute myocardial infarction and one-year clinical outcomes: A prospective cohort study.” International journal of cardiology. Cardiovascular risk and prevention (2026). PMID: 42472246 ↗
L2bCited in: Definition, Synonyms, and Classification - [189]
Kaya AF, Ayhan G, Can V et al.. “An Inflammation-renal composite approach to predict contrast-induced nephropathy in acute myocardial infarction.” International journal of cardiology. Cardiovascular risk and prevention (2026). PMID: 42434342 ↗
L2bCited in: Definition, Synonyms, and Classification - [190]
Stipčević M, Jurin I, Knežević Praveček M et al.. “Psychological Burden and Psychosocial Stress in Younger and Middle-Aged Women with Prior Myocardial Infarction.” Medicina (Kaunas, Lithuania) (2026). PMID: 42356095 ↗
L2bCited in: Definition, Synonyms, and Classification - [191]
Wang F, Ning M, Liu Y. “Prognostic value of X-box binding protein 1 and phospholipase A2 in myocardial injury after ST-segment elevation myocardial infarction: a prospective observational study.” Journal of cardiothoracic surgery (2026). PMID: 42289708 ↗
L2bCited in: Definition, Synonyms, and Classification - [192]
Gorog DA. “New approaches to preventing venous thromboembolism, prognostication in stroke and myocardial infarction, and antiplatelet therapy after spontaneous coronary artery dissection.” Journal of thrombosis and thrombolysis (2025). PMID: 40569553 ↗
L1bCited in: Etiology and Triggering Factors - [193]
Li J, Chen R, Zhao X et al.. “Circulating and Regional Matrix Gla Protein Indicating Plaque Calcification and Prognosis of Patients with ST-Segment Elevation Myocardial Infarction.” Thrombosis and haemostasis (2025). PMID: 40409299 ↗
L2bCited in: Etiology and Triggering Factors - [194]
Maaniitty T, Bär S, Bax JJ et al.. “Quantitative Coronary Atherosclerotic Plaque Burden From CCTA and the Benefit From Lipid-Lowering Medication.” Circulation. Cardiovascular imaging (2026). PMID: 41937634 ↗
L3bCited in: Etiology and Triggering Factors - [195]
Liu X, Wang B, Hao W et al.. “Association of Obstructive Sleep Apnea and Nocturnal Hypoxemia With the Circadian Rhythm of Myocardial Infarction.” Journal of the American Heart Association (2025). PMID: 39868516 ↗
L3bCited in: Etiology and Triggering Factors - [196]
Lu ZF, Cao Y, Abrol S et al.. “Predictive value of plaque features quantified by coronary CT angiography for periprocedural myocardial infarction in Non-ST-Segment elevation acute coronary syndrome.” The international journal of cardiovascular imaging (2025). PMID: 41233700 ↗
L2bCited in: Etiology and Triggering Factors - [197]
Chaturvedi A, Garcia-Garcia HM, Cellamare M et al.. “Outcomes of Primary Percutaneous Intervention for ST-Segment Elevation Myocardial Infarction With Versus Without Spontaneous Coronary Artery Dissection.” The American journal of cardiology (2025). PMID: 40107333 ↗
L2bCited in: Etiology and Triggering Factors - [198]
Wang S, Luo X, Hu S et al.. “Plaque erosion risk and JAK2 V617F variant.” European heart journal (2025). PMID: 40053703 ↗
L3bCited in: Etiology and Triggering Factors - [199]
Hikino K, Koyama S, Ito K et al.. “RNF213 Variants, Vasospastic Angina, and Risk of Fatal Myocardial Infarction.” JAMA cardiology (2024). PMID: 38888930 ↗
L3bCited in: Etiology and Triggering Factors - [200]
Murphy BM, Rogerson MC, Iismaa SE et al.. “Attitudes to and Attendance at Cardiac Rehabilitation After Spontaneous Coronary Artery Dissection.” Journal of cardiopulmonary rehabilitation and prevention (2025). PMID: 40257821 ↗
L3bCited in: Etiology and Triggering Factors - [201]
Kaddoura R, Mahmoud YA, Nasrallah D et al.. “Impact of cardiogenic shock on outcomes in patients with spontaneous coronary artery dissection: a systematic review and meta-analysis.” Panminerva medica (2026). PMID: 41925733 ↗
L2aCited in: Etiology and Triggering Factors - [202]
Budassi S, Biccirè FG, Gatto L et al.. “Independent role of atherosclerotic plaque composition and extension in predicting the risk of cardiac events: a CLIMA substudy.” The international journal of cardiovascular imaging (2024). PMID: 39432135 ↗
L3bCited in: Etiology and Triggering Factors - [203]
Rubino F, Mossop H, Ripley DP et al.. “Invasive vs Conservative Strategy for Frail Older Patients With Myocardial Infarction: A Secondary Analysis of the SENIOR-RITA Randomized Clinical Trial.” JAMA network open (2026). PMID: 42012832 ↗
L1bCited in: Prognosis and Long-term Outcomes - [204]
Ratcovich H, Holmvang L, Sadjadieh G et al.. “Percutaneous Coronary Intervention in Frail Patients Undergoing Transcatheter Aortic Valve Replacement: A NOTION-3 Substudy.” JACC. Cardiovascular interventions (2026). PMID: 41986033 ↗
L1bCited in: Prognosis and Long-term Outcomes - [205]
Sarti A, Verardi FM, Cavazza C et al.. “Diabetes does not attenuate the benefit of physiology-guided complete revascularization in older patients with myocardial infarction.” Cardiovascular diabetology (2026). PMID: 41981421 ↗
L1bCited in: Prognosis and Long-term Outcomes - [206]
Wang Y, Zeng C, Huang YL et al.. “The association of triglyceride-glucose index with acute myocardial infarction and all-cause mortality in patients with coronary artery disease stratified by acute myocardial infarction status: a large-scale retrospective cohort study from South China.” BMJ open (2026). PMID: 42276806 ↗
L2bCited in: Prognosis and Long-term Outcomes - [207]
Miao Y, Shen L, Wang L et al.. “Echocardiographic grading for long-term mortality risk stratification after first-time ST-segment elevation myocardial infarction: a multicentre cohort study.” BMJ open (2026). PMID: 42014156 ↗
L2bCited in: Prognosis and Long-term Outcomes - [208]
Kim S, Jun HJ, Jo G et al.. “Associations of plasma level of soluble LDL receptor with cardiovascular events and mortality in a large prospective cohort study.” Lipids in health and disease (2026). PMID: 41963945 ↗
L2bCited in: Prognosis and Long-term Outcomes - [209]
Wang W, Li Q, Shu L et al.. “Association between stress hyperglycemia ratio and in-hospital mortality in acute myocardial infarction: a dose-response meta-analysis.” BMC cardiovascular disorders (2026). PMID: 42092793 ↗
L2aCited in: Prognosis and Long-term Outcomes - [210]
Zhao Y, Jiang H, Zhao Y et al.. “Development and external validation of an admission-based model for 180-day mortality in diabetic acute myocardial infarction.” Frontiers in endocrinology (2026). PMID: 42466342 ↗
L3bCited in: Prognosis and Long-term Outcomes - [211]
Guimaraes AR, Williams SE, Macmillan MT et al.. “Machine Learning Multiorgan Analysis of Coronary CT Angiography Body Composition, Myocardial Infarction, and Mortality in the SCOT-HEART Trial.” Radiology (2026). PMID: 42377128 ↗
L3bCited in: Prognosis and Long-term Outcomes - [212]
Liu H, Hu S, Zhang Y et al.. “Development and Validation of an Interpretable Machine Learning Model for Predicting 1-Year Cardiac Death After Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction: A Multicenter Study.” Journal of the American Heart Association (2026). PMID: 42333686 ↗
L4Cited in: Prognosis and Long-term Outcomes - [213]
Gopal A, Kamrada C, Awad A et al.. “Association of Baseline SSRI use with post-STEMI outcomes in patients with depression.” International journal of cardiology (2026). PMID: 42203004 ↗
L3bCited in: Prognosis and Long-term Outcomes - [214]
van Steenwijk MPJ, Uitbeijerse LP, Pladet LCA et al.. “Association Between Preadmission β-Blocker Use and Venoarterial Extracorporeal Membrane Oxygenation Weaning Failure in Patients With Cardiogenic Shock.” Journal of the American Heart Association (2026). PMID: 42179258 ↗
L3bCited in: Prognosis and Long-term Outcomes - [215]
Hosseini F, Kang M, Segal T et al.. “Impact of malnutrition on outcomes among elderly ST-Elevation myocardial infarction patients receiving primary percutaneous coronary intervention.” American heart journal (2026). PMID: 42142827 ↗
L3bCited in: Prognosis and Long-term Outcomes - [216]
Lewin D, Nersesian G, Rojas SV et al.. “Impact of Partial- to Full-Support Escalation With Microaxial Flow Pumps Prior to Durable Left Ventricular Assist Device Implantation.” European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2026). PMID: 42087324 ↗
L4Cited in: Prognosis and Long-term Outcomes - [217]
Pesce F, Dini CS, Righini FM et al.. “Optimizing cardiogenic shock outcomes: A system-based network approach.” International journal of cardiology (2026). PMID: 42082006 ↗
L3bCited in: Prognosis and Long-term Outcomes - [218]
Tian J, Wang Z, Wang Y et al.. “Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease.” The New England journal of medicine (2026). PMID: 42456136 ↗
L1bCited in: Special Populations - [219]
Kharatha M, Rezaie S, Talebi SS et al.. “Effect of head and facial massage combined with aromatherapy on sleep quality and delirium in patients with acute myocardial infarction: A randomized controlled trial.” Complementary therapies in medicine (2026). PMID: 42336252 ↗
L1bCited in: Special Populations - [220]
Leissner P, Sundelin R, Rondung E et al.. “Randomized Controlled Trial of Internet-Delivered Cognitive Behavioral Therapy After Myocardial Infarction With Nonobstructive Coronary Arteries or Takotsubo Syndrome.” Journal of the American Heart Association (2026). PMID: 42294783 ↗
L1bCited in: Special Populations - [221]
Mirhosseini SA, Sadrzadeh SA, Semirani-Nezhad D et al.. “Baseline Ejection Fraction as a Modifier of Beta-Blocker Therapeutic Effects in Post-Acute Coronary Syndrome Patients With Non-Reduced Ejection Fraction: A Systematic Review and Meta-Analysis.” Cardiovascular therapeutics (2026). PMID: 42311050 ↗
L1aCited in: Special Populations - [222]
An X, Chen Y, Wang Y et al.. “Association Between Sleep Disorders and Adverse Cardiovascular Outcomes in Patients with Chronic Obstructive Pulmonary Disease: Insights from the UK Biobank.” International journal of chronic obstructive pulmonary disease (2026). PMID: 42306044 ↗
L2bCited in: Special Populations - [223]
Karalis DG, Richter B, Hessen S et al.. “Electronic Health Record Alerts to Improve Lipid Lowering After a Recent Myocardial Infarction.” Journal of the American Heart Association (2026). PMID: 42261954 ↗
L2bCited in: Special Populations - [224]
Wang C, Sakita FM, Prakash T et al.. “Long-Term Implementation and Effectiveness of a Quality Improvement Intervention for Myocardial Infarction in Tanzania.” Annals of global health (2026). PMID: 42404322 ↗
L3bCited in: Special Populations - [225]
Essa H, Balu A, Johnston B et al.. “Impact of new-onset atrial fibrillation on 12-month outcomes and mortality after esophagectomy.” Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus (2026). PMID: 42328848 ↗
L3bCited in: Special Populations - [226]
Emori H, Shiono Y, Yamanobe H et al.. “Incidence of periprocedural myocardial injury and clinical outcomes after rotational atherectomy vs. intravascular lithotripsy.” International journal of cardiology (2026). PMID: 42314849 ↗
L3bCited in: Special Populations - [227]
Armentaro G, Crudo G, Menichelli D et al.. “Prognostic Role of Serum Albumin Levels in Elderly Patients With Non-Valvular Atrial Fibrillation.” European journal of clinical investigation (2026). PMID: 42299459 ↗
L3bCited in: Special Populations - [228]
Al-Naqdi MMA, Alkhammasi MLM, Al-Naqdi BMA. “Mortality Outcome Post-MI after PCI and CABG Interventions.” Global heart (2026). PMID: 42292644 ↗
L3bCited in: Special Populations - [229]
Filev R, Bogov B, Hadjieva R et al.. “Association of Acute-Phase IL-6 and SAA with Cardiovascular Events and Mortality Six Years After COVID-19 Infection: An Observational Cohort Study.” International journal of molecular sciences (2026). PMID: 42278254 ↗
L3bCited in: Special Populations - [230]
Lopez JJ, Volleberg RHJA, Shin D et al.. “OCT-Defined Plaque Morphology and Clinical Outcomes After Percutaneous Coronary Intervention: An ILUMIEN IV Substudy.” JACC. Cardiovascular imaging (2026). PMID: 42547197 ↗
L1bCited in: Etiology and Triggering Factors - [231]
Gi T, Tanaka H, Moriguchi-Goto S et al.. “Sepsis-Related Coronary Endarteritis With Multiple Coronary Artery Thrombi and Acute Myocardial Infarction.” Pathology international (2026). PMID: 42528364 ↗
L4Cited in: Etiology and Triggering Factors - [232]
Schönbeck H, Björkelund A, Møller ES et al.. “A missed diagnosis of acute aortic syndrome is associated with ischaemic ECG changes and an initial suspicion of myocardial infarction: a retrospective observational study.” BMC emergency medicine (2025). PMID: 41315990 ↗
L3bCited in: Differential Diagnosis - [233]
Lindahl B, Thurston AJ, Tew YY et al.. “Change in cardiac troponin T to differentiate acute from chronic myocardial injury in the Emergency Department.” Clinical biochemistry (2025). PMID: 41241321 ↗
L2bCited in: Differential Diagnosis - [234]
Mokhtar WSW, Noor JM, Baharuddin MNA et al.. “Knowledge level of ECG interpretation on STEMI, its equivalents and mimics among emergency department medical officers: a single-centre study.” BMC medical education (2026). PMID: 42252427 ↗
L3bCited in: Differential Diagnosis - [235]
Recchioni T, Manzi G, Caputo A et al.. “Sodium nitroprusside: A comprehensive systematic review of its role across various clinical settings.” Vascular pharmacology (2026). PMID: 41903872 ↗
L1aCited in: Differential Diagnosis - [236]
Pernigo M, Berti M, Renga EM et al.. “Enhancing echocardiographic diagnosis of typical Takotsubo syndrome: validation of IAR and ILAR indexes.” Journal of cardiovascular medicine (Hagerstown, Md.) (2026). PMID: 42349394 ↗
L3bCited in: Differential Diagnosis - [237]
Lin H, Sun Q, Yao W et al.. “Fear of movement and its associated psychosocial factors in patients with acute cardiovascular disease: a retrospective cohort study.” BMC cardiovascular disorders (2026). PMID: 41975277 ↗
L3bCited in: Differential Diagnosis - [238]
Puchongmart C, Lorlowhakarn K, Thiravetyan B et al.. “In-hospital outcomes associated with extracorporeal membrane oxygenation in Takotsubo cardiomyopathy with cardiogenic shock: a propensity-matched analysis of a national cohort.” Journal of cardiovascular medicine (Hagerstown, Md.) (2026). PMID: 41703407 ↗
L3bCited in: Differential Diagnosis - [239]
Huang Q, Zhao P, He Y et al.. “Multiparametric integration of cardiac markers in differentiating myocardial infarction with non-obstructive coronary arteries: LASSO regression.” Heart & lung : the journal of critical care (2025). PMID: 41135216 ↗
L3bCited in: Differential Diagnosis - [240]
Ripon RH, Zahin H, Noman AA et al.. “CDK7 as a Potential Exploratory Biomarker for Distinguishing Acute Myocardial Infarction Subtypes via DDR Pathways: Evidence From a Bangladeshi Cohort.” Clinical cardiology (2026). PMID: 42267702 ↗
L3bCited in: Differential Diagnosis - [241]
Huang M, Lin L, Fan XX et al.. “Development of a machine-learning based diagnosis procedure to distinguish aortic dissection from non-ST-elevation myocardial infarction.” BMC medical informatics and decision making (2026). PMID: 41882701 ↗
L5Cited in: Differential Diagnosis - [242]
Diercks D, Cao M, McHugh M et al.. “Evaluation and management of chest pain from cardiovascular causes in female patients.” BMJ (Clinical research ed.) (2026). PMID: 41617253 ↗
L5Cited in: Differential Diagnosis - [243]
Bertolet M, Carrier FM, Glynn S et al.. “Restrictive vs Liberal Transfusion Strategy After Myocardial Infarction: A Post Hoc Analysis of the MINT Randomized Clinical Trial.” JAMA network open (2026). PMID: 42507445 ↗
L1bCited in: Supportive Care and Complication Management - [244]
Jøns C, Søgaard P, Smilde T et al.. “Pitfalls in the reporting of clinical events in unblinded device trials: analysing performance bias in the BIO|GUARD-MI trial.” Trials (2026). PMID: 42129909 ↗
L1bCited in: Supportive Care and Complication Management - [245]
Bulloni M, Torquati M, Ahola R et al.. “Prediction of in-hospital atrial fibrillation after acute myocardial infarction: a cross-cohort study in Italian and Finnish patients.” International journal of medical informatics (2026). PMID: 42435612 ↗
L3bCited in: Supportive Care and Complication Management - [246]
Franco D, Belohlavek J, Rob D et al.. “Impact of cardiac arrest in patients with cardiogenic shock due to ST-elevation myocardial infarction.” Resuscitation (2026). PMID: 42019600 ↗
L3bCited in: Supportive Care and Complication Management - [247]
Fujimoto H, Komiyama K, Kodera S et al.. “Impella in killip class IV acute myocardial infarction complicated by pulseless ventricular arrhythmia.” Cardiovascular intervention and therapeutics (2026). PMID: 41904306 ↗
L3bCited in: Supportive Care and Complication Management - [248]
Zhou J, Li J, Xu Y et al.. “Association between Percutaneous Coronary Intervention and Long-Term Clinical Outcomes in Patients with Chronic Kidney Disease and Acute Myocardial Infarction.” Cardiorenal medicine (2026). PMID: 42340873 ↗
L2bCited in: Supportive Care and Complication Management - [249]
Pieri M, Altizio S, Pontillo D et al.. “Durable ventricular assist device implantation after acute myocardial infarction: an analysis of the EUROMACS registry.” Journal of cardiovascular medicine (Hagerstown, Md.) (2026). PMID: 42474341 ↗
L4Cited in: Supportive Care and Complication Management - [250]
Daoulah A, M Ladna J, Arabi A et al.. “Postangiography Prediction of Renal Replacement Therapy in Acute Myocardial Infarction-Related Cardiogenic Shock: Least Absolute Shrinkage and Selection Operator Nomogram Development and Validation.” JMIR cardio (2026). PMID: 42160715 ↗
L3bCited in: Supportive Care and Complication Management - [251]
Liu T, Meng Z, Li D et al.. “The association between glycemic variability and atrial fibrillation/in-hospital mortality in white and non-white patients with acute myocardial infarction: A retrospective cohort study.” Journal of the National Medical Association (2026). PMID: 42103517 ↗
L3bCited in: Supportive Care and Complication Management - [252]
Ammoury C, Ramu SK, Rajendran J et al.. “Timing of New-Onset Atrial Fibrillation After Myocardial Infarction: Prognostic Impact and Associated Clinical Characteristics.” The American journal of cardiology (2026). PMID: 42069282 ↗
L3bCited in: Supportive Care and Complication Management - [253]
Li H, Ma Y, Su Y. “Initial intra-aortic balloon pump versus Impella support strategies and short-term outcomes in acute myocardial infarction complicated by cardiogenic shock: a MIMIC-IV cohort study.” BMC cardiovascular disorders (2026). PMID: 42032454 ↗
L4Cited in: Supportive Care and Complication Management - [254]
Todurov M, Todurov B, Mokryk I et al.. “Impact of concomitant intra-aortic balloon pump support on outcomes in patients with acute myocardial infarction-related cardiogenic shock undergoing percutaneous coronary intervention with veno-arterial ECMO: a propensity-matched analysis.” BMC cardiovascular disorders (2026). PMID: 41922989 ↗
L3bCited in: Supportive Care and Complication Management - [255]
Cao JY, Zhou XJ, Zhang LX. “Development and validation of a risk prediction model for in-hospital mortality among patients with acute myocardial infarction complicated by ventricular arrhythmia.” BMC cardiovascular disorders (2026). PMID: 41857533 ↗
L3bCited in: Supportive Care and Complication Management - [256]
Tang W, Yu Y, Bing JY et al.. “Single-Nucleus Transcriptomics Identifies Microglial Interferon Regulatory Factor 5 as a Regulator of Neuroinflammation During Heart Failure Progression After Myocardial Infarction in Rats.” Journal of the American Heart Association (2026). PMID: 42568060 ↗
L5Cited in: Supportive Care and Complication Management - [257]
Stølen TO, Nyman M, Garten K et al.. “Effect of Exercise Training on Myocardial and Residual Scar Electrophysiology in Post-MI Rats.” Circulation. Arrhythmia and electrophysiology (2026). PMID: 42389802 ↗
L5Cited in: Supportive Care and Complication Management - [258]
Zhang F, Liu Y, Liu R et al.. “The role of the bidirectional regulatory network between immune cells and stromal cells in cardiac repair and fibrosis following myocardial infarction.” Frontiers in immunology (2026). PMID: 42389516 ↗
L5Cited in: Supportive Care and Complication Management